CN108430969B - 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 - Google Patents
杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 Download PDFInfo
- Publication number
- CN108430969B CN108430969B CN201780005514.8A CN201780005514A CN108430969B CN 108430969 B CN108430969 B CN 108430969B CN 201780005514 A CN201780005514 A CN 201780005514A CN 108430969 B CN108430969 B CN 108430969B
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- ring
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 73
- 125000000623 heterocyclic group Chemical group 0.000 title abstract description 16
- SUZXWXGJCOCMHU-UHFFFAOYSA-N n-sulfonylbenzamide Chemical class O=S(=O)=NC(=O)C1=CC=CC=C1 SUZXWXGJCOCMHU-UHFFFAOYSA-N 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 286
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- -1 chloro, methyl Chemical group 0.000 claims description 87
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 57
- 125000005843 halogen group Chemical group 0.000 claims description 53
- 208000002193 Pain Diseases 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical group 0.000 claims description 34
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 230000036407 pain Effects 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 abstract description 5
- 239000000651 prodrug Substances 0.000 abstract description 5
- 239000012453 solvate Substances 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 89
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 78
- 201000006417 multiple sclerosis Diseases 0.000 description 68
- 238000006243 chemical reaction Methods 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 58
- 238000000034 method Methods 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
- 239000007787 solid Substances 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000012043 crude product Substances 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 29
- 239000012074 organic phase Substances 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 229910052799 carbon Inorganic materials 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 25
- 125000002950 monocyclic group Chemical group 0.000 description 25
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- 239000011259 mixed solution Substances 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 20
- 125000006413 ring segment Chemical group 0.000 description 20
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 19
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 229910052717 sulfur Inorganic materials 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 210000003722 extracellular fluid Anatomy 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 15
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 14
- 229910003827 NRaRb Inorganic materials 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 10
- 206010053552 allodynia Diseases 0.000 description 10
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- 210000001853 liver microsome Anatomy 0.000 description 10
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 210000001032 spinal nerve Anatomy 0.000 description 9
- 108091006146 Channels Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- 125000005605 benzo group Chemical group 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229910052701 rubidium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 102000004257 Potassium Channel Human genes 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 6
- 201000011384 erythromelalgia Diseases 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 6
- 229960005417 ketanserin Drugs 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 108020001213 potassium channel Proteins 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 5
- 102000004310 Ion Channels Human genes 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 108010052164 Sodium Channels Proteins 0.000 description 5
- 102000018674 Sodium Channels Human genes 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 208000017692 primary erythermalgia Diseases 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 4
- 101150080511 Scn9a gene Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 229940126181 ion channel inhibitor Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- IYDIWHKLLQUHOA-UHFFFAOYSA-N C1(CC1)S(=O)(=O)C=1C(=C(C(=O)N)C=CC=1CN1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl)F Chemical compound C1(CC1)S(=O)(=O)C=1C(=C(C(=O)N)C=CC=1CN1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl)F IYDIWHKLLQUHOA-UHFFFAOYSA-N 0.000 description 3
- BXDFTRAEPXIJTQ-UHFFFAOYSA-N C1(CC1)S(=O)(=O)C=1C(=C(C(=O)N)C=CC=1CN1CCN(CC1)C1=CC(=CC(=C1)Cl)Cl)F Chemical compound C1(CC1)S(=O)(=O)C=1C(=C(C(=O)N)C=CC=1CN1CCN(CC1)C1=CC(=CC(=C1)Cl)Cl)F BXDFTRAEPXIJTQ-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 208000037674 Primary erythromelalgia Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 3
- 229960005132 cisapride Drugs 0.000 description 3
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 210000002977 intracellular fluid Anatomy 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 3
- 229960001233 pregabalin Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- UUODQIKUTGWMPT-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CC=C(C(F)(F)F)C=N1 UUODQIKUTGWMPT-UHFFFAOYSA-N 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LTGDXZXBVOSQGX-UHFFFAOYSA-N C1(CC1)S(=O)(=O)C=1C(=CC(=C(C(=O)N)C=1)F)CN1CCN(CC1)CC1=CC(=CC(=C1)Cl)Cl Chemical compound C1(CC1)S(=O)(=O)C=1C(=CC(=C(C(=O)N)C=1)F)CN1CCN(CC1)CC1=CC(=CC(=C1)Cl)Cl LTGDXZXBVOSQGX-UHFFFAOYSA-N 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- CMIIZHGNVBBREU-UHFFFAOYSA-N ClC=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)CN1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl Chemical compound ClC=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)CN1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl CMIIZHGNVBBREU-UHFFFAOYSA-N 0.000 description 2
- VSORQYRTMSXJKI-UHFFFAOYSA-N ClC=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)CN1CCN(CC1)CC1=CC(=C(C=C1)Cl)C Chemical compound ClC=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)CN1CCN(CC1)CC1=CC(=C(C=C1)Cl)C VSORQYRTMSXJKI-UHFFFAOYSA-N 0.000 description 2
- UGWSCYFRMFEITA-CYBMUJFWSA-N ClC=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)CN1[C@@H](CN(CC1)C1=CC(=C(C=C1)Cl)Cl)C Chemical compound ClC=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)CN1[C@@H](CN(CC1)C1=CC(=C(C=C1)Cl)Cl)C UGWSCYFRMFEITA-CYBMUJFWSA-N 0.000 description 2
- XZECRDHJZUNUCE-UHFFFAOYSA-N ClC=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)OC1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl Chemical compound ClC=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)OC1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl XZECRDHJZUNUCE-UHFFFAOYSA-N 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 2
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940045803 cuprous chloride Drugs 0.000 description 2
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000004980 cyclopropylene group Chemical group 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 208000019865 paroxysmal extreme pain disease Diseases 0.000 description 2
- 238000012402 patch clamp technique Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 239000003195 sodium channel blocking agent Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- OSNSWKAZFASRNG-WNFIKIDCSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical compound O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-WNFIKIDCSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- UZKBSZSTDQSMDR-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 UZKBSZSTDQSMDR-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- KWPQTFXULUUCGD-UHFFFAOYSA-N 3,4,5,7,8,9,10,10a-octahydropyrido[1,2-a][1,4]diazepine Chemical group C1CCN=CC2CCCCN21 KWPQTFXULUUCGD-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XLWSBDFQAJXCQX-UHFFFAOYSA-N 4-(bromomethyl)-1,2-dichlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1Cl XLWSBDFQAJXCQX-UHFFFAOYSA-N 0.000 description 1
- CFPZDVAZISWERM-UHFFFAOYSA-N 4-bromo-1,2-dichlorobenzene Chemical compound ClC1=CC=C(Br)C=C1Cl CFPZDVAZISWERM-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- VHPXWPAGHGHDCK-UHFFFAOYSA-N 5-chloro-4-[(3,4-dichlorophenoxy)methyl]-2-fluoro-n-methylsulfonylbenzamide Chemical compound C1=C(F)C(C(=O)NS(=O)(=O)C)=CC(Cl)=C1COC1=CC=C(Cl)C(Cl)=C1 VHPXWPAGHGHDCK-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 208000026709 Liddle syndrome Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229940124777 Nav1.7 inhibitor Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
- 206010037113 Pseudoaldosteronism Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040744 Sinus headache Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 1
- 101710097939 Sodium channel protein type 9 subunit alpha Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 102100025482 Voltage-dependent T-type calcium channel subunit alpha-1H Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 150000004768 bromobenzenes Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000004862 dioxolanes Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- FIZIYLKEXVIRHJ-LGVAUZIVSA-L disodium;[[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O FIZIYLKEXVIRHJ-LGVAUZIVSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000003861 general physiology Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical group CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N phenyl bromide Natural products BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical group C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
本发明公开了一种杂环取代的N‑磺酰基苯甲酰胺衍生物、其制法与医药上的用途。具体地,本发明公开了式(II)化合物或其药学上可接受的盐、立体异构体、溶剂化合物或前药,及其制备方法和应用,式中各基团的定义详见说明书。
Description
技术领域
本发明属于医药技术领域。具体地,本发明特别涉及一种杂环取代的N-磺酰基苯甲酰胺衍生物及其制备方法和作为钠离子通道(特别是Nav1.7)抑制剂的应用,以及由其制备的药物组合物和药用组合物。
背景技术
最近,英国的Cox等在Nature上首次报道了编码电压门控Nav1.7通道的SCN9A基因突变导致遗传个体无痛症的出人意料研究结果。该遗传突变的个体先天失去痛觉,但机体的其它功能完全正常,此外最近的研究表明,表达在DRG神经元的电压门控Nav1.7通道参与痛信号的产生并发挥控制痛觉信号传入的闸门功能。该研究提示Nav1.7通道可能会成为选择性治疗疼痛并无副作用的药物靶点。
Nav1.7(PN1,SCN9A)VGSC对河豚毒素的阻断敏感,其主要表达于末梢交感神经元和感觉神经元。SCN9A基因已由多种物种(包括人类、大鼠及兔)复制,并且显示人与大鼠基因之间的氨基酸有约90%的一致性。
越来越多的身体证据表明Nav1.7在多种疼痛状态(包括急性、慢性、炎性和/或神经性疼痛)中扮演重要的角色,在人类中,Nav1.7蛋白质积累于神经瘤,特别是引起疼痛的神经瘤。Nav1.7功能增加的突变(不论是遗传性或偶发性)已被认为涉及原发性红斑性肢痛(一种特征为四肢的灼痛和发炎的疾病),和突发性极度疼痛症。有关非选择性钠通道阻断剂利多卡因和美西律可缓和遗传性红斑性肢痛的症状,以及卡马西平可有效地减低PEPD的侵袭的次数和严重度的报道结果与上述观察相一致。Nav1.7在疼痛中扮演的角色的其他证据可见于SCN9A基因的功能丧失的突变的显型。后续的研究已显示会导致SCN9A基因的功能丧失与CIP显型的许多不同的突变。
由于Nav1.7特异地在DRG感觉神经元表达而不在心肌细胞和中枢神经系统等其它组织表达,因此研发其特异阻断剂用于治疗慢性痛,不仅可能提高疗效,且副作用也会大大减少,并且Nav1.7离子通道的选择性抑制剂几乎可用于各种疼痛的治疗。
由于患急性或慢性疼痛疾病的许多患者对目前疼痛疗法响应较差,并且通常对阿片制剂产生抗性和不敏感性。此外,目前使用的钠通道阻断剂对于上述疾病状况的功效在很大程度上受许多副作用的限制。这些副作用包括各种CNS紊乱,比如视力模糊、眩晕、恶心和镇静,以及更潜在地威胁生命的心律失常和心力衰竭。
因此,鉴于目前可用药剂有限的效力和不可接受的副作用,迫切需要开发更加安全有效的镇痛药,使其具有较高功效和较少副作用。而Nav1.7离子通道是开发无成瘾性镇痛药物的重要靶标,目前虽已有专利文献报道了多类Nav1.7离子通道抑制剂,然而在开发高活性Nav1.7离子通道抑制剂的同时还应关注其对其他离子通道,如钾离子通道以及人肝微粒体稳定性的影响,由于与HERG钾离子通道相关的心脏毒性以及预测化合物在肝组织清除率的人肝微粒体稳定性指标对药物开发的影响至关重要,因此开发代谢好的高选择性Nav1.7离子通道抑制剂十分必要。
发明内容
本发明的目的是在现有Nav1.7抑制剂基础上提供一种对Nav1.7钠离子通道具有高度选择性,并具有稳定的肝微粒体代谢稳定性的抑制剂及其在医药上应用。
本发明的第一方面提供了一种式(I)所示的化合物,或其药学上可接受的盐、溶剂化物、立体异构体或前药:
式中,R1、R2、R3、R4各自独立地为氢、羟基、CN、NO2、卤素、-NRaRb、C1-20烷基、C3-20环烷基、C3-20环烷氧基、C2-20烯基、C2-20炔基、C1-20烷氧基、-CHO、-CO-(C1-20烷基)、-CO-(C6-20芳基)、C6-20芳基、-CONRaRb、-C(O)O-(C1-20烷基)、-OC(O)-(C1-20烷基)、-SO2-(C1-20烷基)或-SO2-(C6-20芳基);
R5为氢、C1-20烷基、C3-20环烷基、卤代C1-20烷基;
R6为C6-20芳基、C1-20烷基、C3-20环烷基、C3-8杂环基、-NRaRb;所述C3-8杂环基含1-3个选自N、O、S的杂原子,其中,Ra、Rb各自独立地为氢、C1-20烷基、C3-20环烷基或C6-20芳基;
L1、L2连接在环上的任意不同的位置,各自独立地为一个键、或-C(O)N(Ry)-、-N(Ry)C(O)-、-N(Ry)SO2-、-SO2N(Ry)-、-OC(O)-、-C(O)O-、-(CRyRx)r1(O)r2(CRyRx)r3-、-S(O)-、-SO2-、-N(Ry)-、-O-、-S-、-C(O)-或亚环丙基;其中,Ry、Rx各自独立地为氢、卤素、羟基、CN、NO2、C1-20烷基、卤代C1-20烷基、C3-20环烷基、C2-20烯基、C2-20炔基或C6-20芳基;r1、r3各自独立地为0、1、2或3;r2为0或1;
W1、W2各自独立地为C、N、O或S;
n、m各自独立地为0、1、2或3,且n、m不同时为0;其中,当n为0时或m为0时,W1和W2之间通过单键相连;
(R0)p为环上的任意位置的氢被p个R0取代,p为0、1、2、3、4或5,每个R0相同或不同,各自独立地为氢、氘、C1-20烷基、氘代C1-20烷基或卤代C1-20烷基;或任意两个R0通过单键或-(CH2)p1-连接,p1为1、2或3;
A为C6-20芳基、3至7元单环、8至10元双环、3至7元单杂环、8至10元双杂环、5或6元单环杂芳基环、8至10元双环杂芳基环、苯并3至7元单环、苯并3至7元单杂环、5至6元单环杂芳基环并3至7元单环、5至6元单环杂芳基环并3至7元单杂环;
其中,所述烷基、环烷基、环烷氧基、烯基、炔基、烷氧基、芳基、3至7元单环、8至10元双环、3至7元单杂环、8至10元双杂环、5或6元单环杂芳基环、8至10元双环杂芳基环、苯并3至7元单环、苯并3至7元单杂环、5至6元单环杂芳基环并3至7元单环、或5至6元单环杂芳基环并3至7元单杂环为取代的或未取代的;且所述的取代是指基团中的1-5个氢被选自下组的取代基所取代:卤素、硝基、羟基、氰基、C6-20芳基、C1-20烷基、卤代C1-20烷基、C1-20烷氧基、卤代C1-20烷氧基、C3-20环烷基、卤代C3-20环烷基、C3-20环烷氧基、卤代C3-20环烷氧基、C2-20烯基、卤代C2-20烯基、C2-20炔基、卤代C2-20炔基、C1-20烷硫基、卤代C1-20烷硫基、C1-20烷基氨基、卤代C1-20烷基氨基、硫醇、3元至20元的杂环烷基、3元至20元的杂环烷基氧基、C3-20环烷硫基、卤代C3-20环烷硫基、3元至20元的杂环烷基硫基、氧代基、C1-20羟烷基、羧基、-NRaRb、-C(O)NRaRb、-N(Ra)C(O)-(C1-20烷基)、-N(Ra)SO2-(C1-20烷基)、-SO2N(RaRb)、-C(O)O-(C1-20烷基)、-CHO、-OC(O)-(C1-20烷基)、-SO2-(C1-20烷基)、-SO2-(C6-20芳基)、-CO-(C6-20芳基);Ra、Rb各自独立地为氢、C1-20烷基、C3-20环烷基或C6-20芳基。
在另一优选例中,所述R6为C3-10环烷基、C3-8杂环基。
在另一优选例中,所述R6为环丙基、环丁基、环戊基、环己基。
在另一优选例中,R1、R2、R3、R4各自独立地为氢、卤素、C1-20烷基、C3-20环烷基、C3-20环烷氧基或C1-20烷氧基。
在另一优选例中,R2和R4为氢,且R1、R3各自独立地为氢、卤素、C3-20环烷基、C1-20烷基、C3-20环烷氧基或C1-20烷氧基。
在另一优选例中,R5为氢。
在另一优选例中,A为C6-20芳基或5或6元单环杂芳基环;所述的芳基或5或6元单环杂芳基环为取代的或未取代的;且所述的取代是指基团中的1-5个氢被选自下组的取代基所取代:卤素、C1-20烷基、卤代C1-20烷基、C1-20烷氧基、卤代C1-20烷氧基、C3-20环烷基、和C3-20环烷氧基。
在另一优选例中,所述C6-20芳基为苯基;所述5或6元单环杂芳基环为吡啶基。
在另一优选例中,所述苯基为其中R1’、R2’、R3’、R4’、R5’各自独立地为氢、卤素、硝基、羟基、氰基、C6-20芳基、C1-20烷基、卤代C1-20烷基、卤代C1-20烷氧基、C1-20烷氧基、C3-20环烷基、卤代C3-20环烷基、C3-20环烷氧基、卤代C3-20环烷氧基、C2-20烯基、卤代C2-20烯基、C2-20炔基、卤代C2-20炔基、-NRaRb、-C(O)NRaRb、-N(Ra)C(O)-(C1-20烷基)、-N(Ra)SO2-(C1-20烷基)、-SO2N(RaRb)、-C(O)O-(C1-20烷基)、-CHO、-OC(O)-(C1-20烷基)、-SO2-(C1-20烷基)、-SO2-(C6-20芳基)、-CO-(C1-20烷基)、-CO-(C6-20芳基);和/或
所述吡啶基为其中R21、R31、R41、R51、R12、R32、R42、R52、R13、R23、R43、R53各自独立地为氢、卤素、硝基、羟基、氰基、C6-20芳基、C1-20烷基、卤代C1-20烷基、卤代C1-20烷氧基、C1-20烷氧基、C3-20环烷基、卤代C3-20环烷基、C3-20环烷氧基、卤代C3-20环烷氧基、C2-20烯基、卤代C2-20烯基、C2-20炔基、卤代C2-20炔基、-NRaRb、-C(O)NRaRb、-N(Ra)C(O)-(C1-20烷基)、-N(Ra)SO2-(C1-20烷基)、-SO2N(RaRb)、-C(O)O-(C1-20烷基)、-CHO、-OC(O)-(C1-20烷基)、-SO2-(C1-20烷基)、-SO2-(C6-20芳基)、-CO-(C1-20烷基)、-CO-(C6-20芳基);Ra、Rb如上所定义。
在另一优选例中,R1’、R2’、R3’、R4’、R5’各自独立地为氢、卤素、C1-20烷基、卤代C1-20烷基、卤代C1-20烷氧基、C1-20烷氧基、C3-20环烷基、C3-20环烷氧基。
在另一优选例中,R21、R31、R41、R51、R12、R32、R42、R52、R13、R23、R43、R53各自独立地为氢、卤素、C1-20烷基、卤代C1-20烷基、卤代C1-20烷氧基、C1-20烷氧基、C3-20环烷基、C3-20环烷氧基。
在另一优选例中,L1为-(CRyRx)r1(O)r2(CRyRx)r3-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0、1、2或3;r2为0或1。
在另一优选例中,r2为0。
在另一优选例中,
(i)r1、r3为0;r2为1;
(ii)r1为1、2或3;r2为1;r3为0;
(iii)r1为0;r2为1;r3为1、2或3;或
(iv)r1、r2、r3为0。
在另一优选例中,W2为N、O、S或C,当W2为O或S时,L2与环上除W1和W2以外的其它任意碳原子连接,当W2为N或C时,L2与环上除W1以外的其它任意环原子连接。较佳地,L2与W2连接。
在另一优选例中,L2为一个键,A与环上除W1以外的其它任意环原子连接。
在另一优选例中,L2为一个键,W2为N、O、S或C,当W2为O或S时,A与环上除W1和W2以外的其它任意碳原子连接,当W2为N或C时,A与环上除W1以外的其它任意环原子连接。
在另一优选例中,W1为N、O、S或C,当W1为O或S时,L1与环上除W1和W2以外的其它任意碳原子连接,当W1为N或C时,L1与环上除W2以外的其它任意环原子连接,较佳地,L1与W1连接。
在另一优选例中,所述化合物为式(II)所示化合物:
式中,R0、R1、R2、R3、R4、R5、R6、A、L1、W1、W2、n、p、m如权利要求1所定义。
在另一优选例中,每个R0相同或不同,各自独立地为氢。
在另一优选例中,A为C6-20芳基或5或6元单环杂芳基环。
在另一优选例中,A为苯基或吡啶基;所述的苯基或吡啶基为取代的或未取代的;且所述的取代是指基团中的1-5个氢被选自下组的取代基所取代:卤素、C1-20烷基、卤代C1-20烷基、C1-20烷氧基、卤代C1-20烷氧基、C3-20环烷基、和C3-20环烷氧基。
在另一优选例中,L1为一个键、或-(CRyRx)r1(O)r2(CRyRx)r3-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0、1、2或3;r2为0或1。
在另一优选例中,所述化合物为式(III)所示化合物:
式中,R0、R1、R2、R3、R4、R5、R6、Rx、Ry、r1、r2、r3、A、W1、W2、n、p、m如权利要求1所定义。
在另一优选例中,式(III)化合物中,W1为N、O、S或C,当W1为O或S时,(CRyRx)r1与环上除W1和W2以外的其它任意碳原子连接,当W1为N或C时,(CRyRx)r1与环上除W2以外的其它任意环原子连接,r1如上所定义。
在另一优选例中,W2为N。
在另一优选例中,W1为N、O、S或C。
在另一优选例中,选自:且L1为一个键、或-(CRyRx)r1(O)r2(CRyRx)r3-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0、1、2或3;r2为0或1;每个R0相同或不同,各自独立地为氢。
在另一优选例中,所述化合物为式(IV)所示化合物:
式中,R0、R1、R2、R3、R4、R5、R6、Rx、Ry、r1、r2、r3、A、W2、n、p、m定义如前;W1为N或C。
在另一优选例中,r2为0。
在另一优选例中,r1、r3为0;r2为1。
在另一优选例中,r1为1、2或3;r2为1;r3为0。
在另一优选例中,r1为0;r2为1;r3为1、2或3。
在另一优选例中,r1、r2、r3为0。
在另一优选例中,所述化合物为式(V)所示化合物:
式中,R0、R1、R2、R3、R4、R5、R6、L1、W1、W2、n、p、m定义如前;R1’、R2’、R3’、R4’、R5’各自独立地为氢、卤素、硝基、羟基、氰基、C6-20芳基、C1-20烷基、卤代C1-20烷基、卤代C1-20烷氧基、C1-20烷氧基、C3-20环烷基、卤代C3-20环烷基、C3-20环烷氧基、卤代C3-20环烷氧基、C2-20烯基、卤代C2-20烯基、C2-20炔基、卤代C2-20炔基、-NRaRb、-C(O)NRaRb、-N(Ra)C(O)-(C1-20烷基)、-N(Ra)SO2-(C1-20烷基)、-SO2N(RaRb)、-C(O)O-(C1-20烷基)、-CHO、-OC(O)-(C1-20烷基)、-SO2-(C1-20烷基)、-SO2-(C6-20芳基)、-CO-(C1-20烷基)、-CO-(C6-20芳基);Ra、Rb如上所定义。
在另一优选例中,R1’、R2’、R3’、R4’、R5’各自独立地为氢、卤素、C1-20烷基、卤代C1-20烷基、卤代C1-20烷氧基、C1-20烷氧基、C3-20环烷基。
在另一优选例中,式(V)化合物中,L1为-(CRyRx)r1(O)r2(CRyRx)r3-,r1、r2、r3如上所定义。
在另一优选例中,式(V)化合物中,W1为N、O、S或C,当W1为O或S时,L1与环上除W1和W2以外的其它任意碳原子连接,当W1为N或C时,L1与环上除W2以外的其它任意环原子连接,较佳地,L1与W1连接。
在另一优选例中,式(V)化合物中,W2为N。
在另一优选例中,R1、R2、R3、R4各自独立地为氢、卤素、C1-20烷基、C3-20环烷基;
R5为氢;
R6为C1-20烷基、-NRaRb;
其中,Ra、Rb各自独立地为氢、或C1-20烷基;
W1、W2各自独立地为C、O、S或N;
L2为一个键;
L1为一个键、或-(CRyRx)r1(O)r2(CRyRx)r3-、-O-或-C(O)-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0或1;r2为0或1;
n、m各自独立地为1或2;
(R0)p为环上的任意位置的氢被p个R0取代,p为0;
A为苯基;
且当W1和/或W2为O或S时,L1和A分别与环上除W1和W2以外的其它任意碳原子连接;
当W1和/或W2为N或C时,A与环上除W1以外的其它任意环原子连接,L1与环上除W2以外的其它任意环原子连接;
其中,所述烷基、环烷基或苯基为取代的或未取代的;且所述的取代是指基团中的1-5个氢被选自下组的取代基所取代:卤素、C1-20烷基、卤代C1-20烷基、C1-20烷氧基、卤代C1-20烷氧基。
在另一优选例中,R2和R4为氢,且R1、R3各自独立地为卤素、C3-6环烷基、C1-3烷基、C3-6环烷氧基或C1-3烷氧基。
在另一优选例中,L2为一个键(表示A与环上除W1以外的其它任意环原子连接),或为-(CH2)r1(O)r2(CH2)r3-、-S-、-C(O)-、-S(O)-、-SO2-或-N(Ry)-,其中r1、r2、r3、Ry的定义如上所述。
在另一优选例中,所述化合物为式(I)~(V)中任一所示化合物,其中,R1、R2、R3、R4各自独立地为氢、卤素、C1-20烷基、C3-20环烷基;
R5为氢;
R6为C1-20烷基、-NRaRb;其中,Ra、Rb各自独立地为氢、C1-20烷基。
在另一优选例中,A为C6-20芳基或5或6元单环杂芳基环。
在另一优选例中,L2为一个键;或L1为一个键、或-(CRyRx)r1(O)r2(CRyRx)r3-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0、1、2或3;r2为0或1。
在另一优选例中,每个R0相同或不同,各自独立地为氢。
A为C6-20芳基或5或6元单环杂芳基环;
L1为一个键、或-(CRyRx)r1(O)r2(CRyRx)r3-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0、1、2或3;r2为0或1;
每个R0相同或不同,各自独立地为氢;
所述烷基、环烷基、芳基、5或6元单环杂芳基环为取代的或未取代的;且所述的取代是指基团中的1-5个氢被选自下组的取代基所取代:卤素、硝基、羟基、氰基、C6-20芳基、C1-20烷基、卤代C1-20烷基、C1-20烷氧基、卤代C1-20烷氧基、C3-20环烷基、卤代C3-20环烷基、C3-20环烷氧基、卤代C3-20环烷氧基、C2-20烯基、卤代C2-20烯基、C2-20炔基、卤代C2-20炔基、C1-20烷硫基、卤代C1-20烷硫基、C1-20烷基氨基、卤代C1-20烷基氨基、硫醇、3元至20元的杂环烷基、3元至20元的杂环烷基氧基、C3-20环烷硫基、卤代C3-20环烷硫基、3元至20元的杂环烷基硫基、氧代基、C1-20羟烷基、羧基、-NRaRb、-C(O)NRaRb、-N(Ra)C(O)-(C1-20烷基)、-N(Ra)SO2-(C1-20烷基)、-SO2N(RaRb)、-C(O)O-(C1-20烷基)、-CHO、-OC(O)-(C1-20烷基)、-SO2-(C1-20烷基)、-SO2-(C6-20芳基)、-CO-(C6-20芳基);Ra、Rb各自独立地为氢、C1-20烷基、C3-20环烷基或C6-20芳基。
在另一优选例中,A为苯基或吡啶基;所述的苯基或吡啶基为取代的或未取代的;且所述的取代是指基团中的1-5个氢被选自下组的取代基所取代:卤素、C1-20烷基、卤代C1-20烷基、C1-20烷氧基、卤代C1-20烷氧基、C3-20环烷基、C3-20环烷氧基。
L1为一个键、或-(CRyRx)r1(O)r2(CRyRx)r3-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0、1、2或3;r2为0或1;
每个R0相同或不同,各自独立地为氢。
在另一优选例中,r1为0;r3为1;r2为0。
L1为一个键、或-(CRyRx)r1(O)r2(CRyRx)r3-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0、1、2或3;r2为0或1;
每个R0相同或不同,各自独立地为氢。
在另一优选例中,r1、r3为0;r2为1。
L1为一个键、或-(CRyRx)r1(O)r2(CRyRx)r3-;其中,Ry、Rx各自独立地为氢;r1、r3各自独立地为0、1、2或3;r2为0或1;
每个R0相同或不同,各自独立地为氢。
在另一优选例中,r1为1、2或3;r2为1;r3为0。
在另一优选例中,r1为1;r2为1;r3为0。
在另一优选例中,R1、R3各自独立地为氢、卤素、C1-20烷基或C3-20环烷基;R2和R4为氢。
在另一优选例中,C1-20烷基为甲基、乙基、正丙基、异丙基、正丁基。
在另一优选例中,C3-20环烷基为环丙基。
在另一优选例中,卤代C1-20烷基为三氟甲基。
在另一优选例中,卤代C1-20烷氧基为三氟甲氧基、三氟乙氧基、二氟甲氧基。
在另一优选例中,C1-20烷氧基为甲氧基、乙氧基、异丙氧基、叔丁氧基、异丁氧基。
在另一优选例中,C3-20环烷氧基为环丙氧基。
在另一优选例中,卤素为氟或氯。
在另一优选例中,所述化合物选自下组:
在另一优选例中,所述化合物选自下组:
在另一优选例中,所述的R1、R2、R3、R4、R5、R6、Ra、Rb、L1、Ry、Rx、W1、W2、n、m、R0、A等各自独立地为实施例中各具体式II化合物中相应的基团。
在另一优选例中,本发明的式II化合物为实施例部分中所注备的各具体化合物,尤其是Z-80至Z-197中任一化合物。
在另一优选例中,所述化合物为本申请实施例所制备的化合物。
本发明第二方面提供了一种药物组合物,所述组合物包括本发明第一方面所述的化合物、或其药学上可接受的盐、溶剂化物、立体异构体或前药;以及药学可接受的载体。
本发明第三方面提供了如本发明第一方面所述的化合物、或其药学上可接受的盐、溶剂化物、立体异构体或前药,或本发明第二方面所述药物组合物在制备治疗疾病或病症的药物中的应用。
在另一优选例中,所述疾病或病症选自疼痛、抑郁症、心血管疾病、呼吸系统疾病、精神疾病或其组合。
在另一优选例中,所述疾病或病症选自与HIV相关的疼痛、HIV治疗诱导的神经病变、三叉神经痛、带状疱疹后神经痛、急性疼痛、热敏感、结节病、肠易激综合征、克罗恩病、与多发性硬化(MS)有关的疼痛、肌萎缩性侧索硬化(ALS)、糖尿病性神经病变、周围神经病变、关节炎、类风湿性关节炎、骨关节炎、动脉粥样硬化、突发性张力障碍、肌无力综合征、肌强直、恶性高热、囊性纤维化、假性醛固酮增多症、横纹肌溶解症、甲状腺功能减退、双相抑郁症、焦虑症、精神分裂症、钠通道毒素相关病症、家族性红斑性肢痛症、原发性红斑性肢痛症,家族性直肠疼痛、癌症、癫痫、局部和全身强直性发作、不宁腿综合征、心律失常、纤维肌痛、在由中风或神经损伤导致的缺血性疾病状态下的神经保护、快速性心律失常、心房颤动和心室颤动。
在另一优选例中,所述疼痛选自神经性疼痛、炎性疼痛、内脏疼痛、癌症疼痛、化疗疼痛、创伤疼痛、手术疼痛、手术后疼痛、生产疼痛、分娩疼痛、牙痛、慢性疼痛、持续性疼痛、外周介导的疼痛、中枢介导的疼痛、慢性头痛、偏头痛、窦性头痛、紧张性头痛、幻肢痛、周围神经损伤、三叉神经痛、带状疱疹后神经痛、急性疼痛、家族性红斑性肢痛症、原发性红斑性肢痛症、家族性直肠疼痛或纤维肌痛或其组合。
本发明第四方面提供了一种治疗哺乳动物疾病或病症的方法,所述方法包括给需要的对象(如哺乳动物)施用治疗有效量的本发明第一方面所述的化合物,或其药学上可接受的盐、溶剂化物、立体异构体或前药,或本发明第二方面所述的药物组合物。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
附图说明
图1显示了化合物Z-164在脊神经结扎大鼠模型中大鼠冷痛觉测试基线。
图2显示了化合物Z-164在脊神经结扎大鼠模型中抑制冷刺激痛觉超敏效果。
具体实施方式
本发明人经过广泛而深入的研究,意外地发现了本发明的杂环取代的N-磺酰基苯甲酰胺衍生物对Nav1.7钠离子通道具有高度选择性,并具有稳定的肝微粒体代谢稳定性。同时在疼痛模型测试中还显示出明显的镇痛效果,因此本发明的系列化合物可开发成用于广泛疼痛的治疗的药物。在此基础上,发明人完成了本发明。
术语定义
如本文所用,“C1-20烷基”指包含1至20个碳原子的直链和支链的饱和的脂族烃基,如下定义类似;更优选为C1-10烷基,非限制性的例子包括:甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基,及其各种支链异构体等;更优选为C1-6烷基,最优选为C1-3烷基。
如本文所用,“烯基”指至少由两个碳原子和至少一个碳-碳双键组成的如上定义的脂族烃基,“C2-20烯基”是指包含2至20个碳原子的直链和支链的烯基,如下定义类似;更优选为C2-10烯基;更优选为C2-6烯基;最优选C2-4烯基,例如乙烯基、1-丙烯基、2-丙烯基、1-、2-或3-丁烯基等。
如本文所用,“炔基”指至少由两个碳原子和至少一个碳-碳三键组成的如上所定义的脂族烃基,“C2-20炔基”指包含2至20个碳原子的直链和支链的炔基,如下定义类似;更优选为C2-10炔基;更优选为C2-6炔基;更优选为C2-4炔基;例如乙炔基、1-丙炔基、2-丙炔基、1-、2-或3-丁炔基等。
如本文所用,“环烷基”指饱和或部分不饱和单环或多环环状烃基,“C3-20环烷基”是指包含3至20个碳原子的环烃基,如下定义类似;更优选为C3-10环烷基;更优选为C3-8环烷基;最优选为C3-6环烷基。单环环烷基的非限制性实施例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基、金刚烷基等,优选环丙基、环戊基、环己烯基。多环环烷基的非限制性实施例包括螺环、稠环和桥环的环烷基。
如本文所用,“杂环烷基”和“杂环基”可互换使用,指饱和或部分不饱和单环或多环环状烃基,优选为3元至20元的杂环烷基(是指杂环烷基包含3至20个环原子,且其中一个或多个环原子选自氮、氧或S(O)t(其中t是整数0至2)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子为碳);更优选为3元至10元的杂环烷基,其中1~3个环原子是杂原子;更优选为3元至6元的杂环烷基;更优选为5元至6元的杂环烷基。单环杂环基的非限制性实施例包括吡咯烷基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、吡喃基、四氢呋喃基等。多环杂环基的非限制性实施例包括螺环、稠环和桥环的杂环基。
如本文所用,“部分不饱和”是指含有一个或多个不饱和键但不具有完全共轭的π电子系统。
如本文所用,“C1-20烷氧基”指-O-(C1-20烷基),其中烷基的定义如上所述。优选C1-10烷氧基,更优选C1-6烷氧基,最优选C1-3烷氧基。非限制性实施例包含甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、叔丁氧基、异丁氧基、戊氧基等。
如本文所用,“C3-20环烷氧基”指-O-(C3-20环烷基),其中环烷基的定义如上所述。优选C3-10环烷氧基,优选C3-8环烷氧基,更优选C3-6环烷氧基。非限制性实施例包含环丙氧基、环丁氧基、环戊氧基、环己氧基等。
如本文所用,“C6-20芳基”指具有共轭的π电子体系的全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,指含有6至20个碳原子的芳基;更优选为C6-12芳基,更优选苯基和萘基,最优选苯基。
如本文所用,“一个键”指由其连接的两个基团通过一个共价键连接。
如本文所用,“卤素”指氟、氯、溴或碘。
如本文所用,“卤代”指基团中一个或多个(如1、2、3、4或5个)氢被卤素所取代。
例如,“卤代C1-20烷基”指烷基被一个或多个(如1、2、3、4或5个)卤素取代,其中烷基的定义如上所述。优选为卤代C1-10烷基,更优选为卤代C1-6烷基,最优选为卤代C1-3烷基。卤代C1-20烷基的例子包括(但不限于)一氯乙基、二氯甲基、1,2-二氯乙基、一溴乙基、一氟乙基、一氟甲基、二氟甲基、三氟甲基等。
又例如,“卤代C1-20烷氧基”指烷氧基被一个或多个(如1、2、3、4或5个)卤素取代,其中烷氧基的定义如上所述。优选为卤代C1-10烷氧基,更优选为卤代C1-6烷氧基,最优选为卤代C1-3烷氧基。包括(但不限于)三氟甲氧基、三氟乙氧基、一氟甲氧基、一氟乙氧基、二氟甲氧基、二氟乙氧基等。
又例如,“卤代C3-20环烷基”指环烷基被一个或多个(如1、2、3、4或5个)卤素取代,其中环烷基的定义如上所述。优选为卤代C3-10环烷基,更优选为卤代C3-8环烷基,最优选为卤代C3-6环烷基。包括(但不限于)三氟环丙基、一氟环丙基、一氟环己基、二氟环丙基、二氟环己基等。
如本文所用,“氘代C1-20烷基”指烷基被一个或多个(如1、2、3、4或5个)氘原子取代,其中烷基的定义如上所述。优选为氘代C1-10烷基,更优选为氘代C1-6烷基,最优选为氘代C1-3烷基。氘代C1-20烷基的例子包括(但不限于)单氘代甲基、单氘代乙基、二氘代甲基、二氘代乙基、三氘代甲基、三氘代乙基等。
如本文所用,“C1-20羟烷基”指被羟基取代的C1-20烷基,其中烷基的定义如上所述。优选为C1-10羟烷基,更优选为C1-6羟烷基,最优选为C1-3羟烷基。
如本文所用,“羧酸酯基”指-C(O)O-(C1-20烷基)或(C3-20环烷基),其中烷基、环烷基的定义如上所述。
如本文所用,“C1-20烷硫基”指-S-(C1-20烷基),其中烷基的定义如上所述。优选为C1-10烷硫基,更优选为C1-6烷硫基,最优选为C1-3烷硫基。
如本文所用,“C1-20烷基氨基”指-(C1-20烷基)-NH2或-NH2-(C1-20烷基),其中烷基的定义如上所述。优选为C1-10烷基氨基,更优选为C1-6烷基氨基,最优选为C1-3烷基氨基。
如本文所用,“C3-20环烷硫基”指-S-(C3-20环烷基),其中环烷基的定义如上所述。优选为C3-10环烷硫基,更优选为C3-8环烷硫基,最优选为C3-6环烷硫基。
如本文所用,“3元至20元的杂环烷基硫基”指-S-(3元至20元的杂环烷基),其中杂环烷基的定义如上所述。优选为3元至10元的杂环烷基硫基。
如本文所用,“3元至20元的杂环烷基氧基”指-O-(3元至20元的杂环烷基),其中杂环烷基的定义如上所述。优选为3元至10元的杂环烷基氧基。
如本文所用,“杂芳基环”与“杂芳基”可互换使用,是指具有5到10个环原子,优选5或6元单环杂芳基或8至10元双环杂芳基;环阵列中共享6、10或14个π电子;且除碳原子外还具有1到5个杂原子的基团。“杂原子”是指氮、氧或硫。
如本文所用,“3至7元单环”是指含3至7个环原子的饱和或部分不饱和的全碳单环。优选5至6元。单环的实例包括(但不限于):环丙基环、环丁基环、环戊基环、环戊烯基环、环己基环、环己烯基环、环己二烯基环、环庚基环、环庚三烯基环、环辛基环等。
如本文所用,“3至7元单杂环”是指3至7元单环中的1、2或3个碳原子被选自氮、氧或硫的杂原子所取代。优选5至6元。单杂环的实例包括(但不限于)四氢呋喃环、四氢噻吩环、吡咯烷基环、哌啶环、吡咯啉环、噁唑烷环、哌嗪环、二氧戊环、吗啉环、硫代吗啉环、高哌嗪环、吡喃环等。
如本文所用,“8至10元双杂环”是指8至10元双环中的1、2、3、4或5个碳原子被选自氮、氧或硫的杂原子所取代。双杂环的实例包括(但不限于)四氢喹啉环、四氢异喹啉环、十氢喹啉环等。
如本文所用,“5至6元单环杂芳基环”是指含5至6个环原子的单杂芳基环,例如包括(但不限于):噻吩环、N-烷基吡咯环、呋喃环、噻唑环、咪唑环、噁唑环、吡咯环、吡唑环、三唑环、四唑环、异噁唑环、噁二唑环、噻二唑环、吡啶环、哒嗪环、嘧啶环、吡嗪环等。
如本文所用,“8至10元双环杂芳基环”是指含8至10个环原子的双杂芳基环,例如包括(但不限于):苯并呋喃环、苯并噻吩环、吲哚环、异吲哚环、喹啉环、异喹啉环、吲唑环、苯并噻唑环、苯并咪唑环、喹唑啉环、喹喔啉环、噌啉环、酞嗪环。
如本文所用,“苯并3至7元单环或苯并3至7元单杂环”是指含3至7个环原子的单环或单杂环稠合于苯环上形成的双环结构,优选苯并5至6元单环或苯并5至6元单杂环。非限制性实施例包含:
如本文所用,“5至6元单环杂芳基环并3至7元单环或5至6元单环杂芳基环并3至7元单杂环”是指3至7元单环或3至7元单杂环稠合于5至6元单环杂芳基环上形成的双环结构,非限制性实施例包含:
如本文所用,“取代的”指基团中的一个或多个氢原子,优选为1~5个氢原子彼此独立地被相应数目的取代基取代,更优选为1~3个氢原子彼此独立地被相应数目的取代基取代。不言而喻,取代基仅处在它们的可能的化学位置,本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如,具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
如本文所用,烷基可以是取代的或未取代的,烯基可以是取代的或非取代的,炔基可以是取代的或非取代的,环烷基可以是取代的或未取代的,杂环基可以是取代的或未取代的,烷氧基可以是任选取代的或未取代的,环烷氧基可以是任选取代的或未取代的,芳基可以是取代的或未取代的,3至7元单环可以是取代的或未取代的,3至7元单杂环可以是取代的或未取代的,8至10元双环可以是取代的或未取代的,8至10元双杂环可以是取代的或未取代的,苯并3至7元单环或苯并3至7元单杂环可以是取代的或未取代的,5至6元单环杂芳基环并3至7元单环或5至6元单环杂芳基环并3至7元单杂环可以是取代的或未取代的,上述基团为取代时,取代基优选为1至5个以下基团,独立地选自C1-20烷基、卤代C1-20烷基、C2-20烯基、C2-20炔基、C1-20烷氧基、C1-20烷硫基、C1-20烷基氨基、卤素、硫醇、羟基、硝基、氰基、C3-20环烷基、3元至20元的杂环基、C6-20芳基、5或6元单环杂芳基或8至10元双环杂芳基、C3-20环烷氧基、3元至20元的杂环烷基氧基、C3-20环烷硫基、3元至20元的杂环烷基硫基、氧代基、氨基、C1-20羟烷基、羧基或羧酸酯基。
制备方法
本发明提供了式(I)化合物的制备方法,本发明中的化合物可以通过多种合成操作容易地制备,这些操作是所属领域技术人员熟练掌握的。这些化合物的示例性制备方法可以包括(但不限于)下文所述的流程。
本发明式(I)化合物可以参照下述合成路线进行制备,在具体操作过程中,可以根据需要对方法中的步骤进行扩展或合并。
路线1
步骤1:可先通过例如草酰氯、羰基二咪唑(CDI)、丙基膦酸酐、基于脲的酰胺偶联剂或碳二亚胺等试剂激活式(I-a)化合物中的羧基,随后在亲和性碱,例如4-二甲氨基吡啶、N,N-二甲基氨基丙基-N’-乙基碳二亚胺、4-二甲氨基吡啶/N,N-二异丙基乙胺的存在下与式(I-b)化合物中的磺酰胺基团发生置换反应,生成式(I-c)化合物。
步骤2:式(I-c)化合物与式(I-d)化合物在碱体系的存在下,通过取代反应(例如亲和取代反应等)或偶联反应(如Suzuki偶联等)生成式(I-e)化合物,合适的碱体系包括存在于DMSO的叔丁醇钾、存在于DMF中的氢化钠、存在于DMF的碳酸钾等。
步骤3:式(I-e)化合物可与式(I-f)化合物发生取代反应生成式(I)化合物,式(I-f)中的Lev为离去基团,包括(但不限于)三氟甲磺酸酯;氯、溴、碘;磺酸酯基,如甲磺酸酯、甲苯磺酸酯、对溴苯磺酸酯、对甲苯磺酸酯等;酰氧基,如乙酰氧基、三氟乙酰氧基等。
路线2
式(I-d)化合物可先与式(I-f)化合物发生取代反应生成式(I-g)化合物,随后与式(I-c)化合物反应生成式(I)化合物,反应条件分别同路线1中的步骤3和步骤2。
以上各步骤中的反应均是本领域技术人员已知的常规反应。如无特殊说明,合成路线中所使用的试剂和原料化合物均可市购得到,或本领域技术人员根据所设计的不同化合物结构参考已知方法制备得到。
与现有技术相比,本发明的主要优点在于:
提供了一系列结构新颖的杂环取代的N-磺酰基苯甲酰胺衍生物,其对Nav1.7钠离子通道具有高度选择性,并具有稳定的肝微粒体代谢稳定性,可用作广泛疼痛治疗的药物。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。除非另行定义,本文所用的术语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或同等的方法及材料皆可应用于本发明中。
如本文所用,DMF为二甲基甲酰胺,DMSO为二甲基亚砜,THF为四氢呋喃,DIPEA为N,N-二异丙基乙胺,EA为乙酸乙酯,PE为石油醚,BINAP为(2R,3S)-2,2’-双二苯膦基-1,1’-联萘,LiHMDS为双三甲基硅基胺基锂,THF为四氢呋喃,HATU为2-(7-偶氮苯并三氮唑)-N,N,N’,N’-四甲基脲六氟磷酸酯,n-BuLi为正丁基锂,DCM为二氯甲烷,DME乙二醇二甲醚,NBS为N-溴代丁二酰亚胺,Pd2(dba)3为三(二亚苄基丙酮)二钯,CDI为N,N’-羰基二咪唑,DBU为1,5-二氮杂二环[5.4.0]十一-5-烯,Pd(dppf)Cl2为[1,1’-双(二苯基膦基)二茂铁]二氯化钯,DIAD为偶氮二甲酸二异丙酯,EDCI为1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐,DMAP为4-二甲氨基吡啶,LDA为二异丙基氨基锂。
如本文所用,室温是指约为25℃。
化合物13-a的制备方法:
步骤a:将化合物13-a-1(50g,0.40mol)加入到浓盐酸(400ml)中,混合物冷却到0℃,滴加亚硝酸钠(28.6g,0.44mol)的水(100ml)溶液。混合物在0℃反应0.5h后,加入氯化亚铜(91.68g,0.48mol)。混合物在室温搅拌0.5h后,加热到100℃搅拌1h。冷却后过滤,滤液用石油醚(500ml x 2)萃取,有机相用饱和食盐水洗涤(500ml),无水硫酸钠干燥,过滤,滤液减压蒸干,所得粗品通过柱层析提纯(eluent/PE∶EA=10∶1),得到无色油状化合物13-a-2(24.1g,产率:41%)。
步骤b:将化合物13-a-2(18.72g,130mmol)溶解在无水THF(200ml)中,冷却至-78℃,氮气保护下,滴加n-BuLi(62.4ml,2.4M/L,248mmol)。混合物在-78℃搅拌1h,然后倒到干冰上。混合物在-78℃搅拌1h,然后在室温下搅拌1h。混合物倒入2N盐酸水溶液(200ml)中,用乙酸乙酯(250ml)萃取。分出有机相用食盐水(200ml)洗涤。无水硫酸钠干燥,过滤。滤液用旋转蒸发仪旋干得白色固体13-a-3(9.1g,产率:37%).ESI-MS[M-H]-:187。纯度=80%(UV214)。
步骤c:将化合物13-a-3(9.1g,48mmol)溶解在无水DCM(150mL)中,冷却至0℃,分别加入1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐(13.76g,72mmol),DMAP(11.8g,96mmol),甲基磺酰胺(9.12g,96mmol),N,N-二异丙基乙胺(18.57g,114mmol)。混合物在室温搅拌18h后,倒入2N盐酸水溶液(100ml)中,混合物在室温搅拌0.5h后,分出有机相用食盐水(100ml)洗涤。无水硫酸钠干燥,过滤。滤液用旋转蒸发仪旋干得白色固体13-a-4(9.6g,产率:78%).ESI-MS[M+H]+:266.0。纯度=91%(UV214)。
步骤d:将化合物13-a-4(7.95g,30mmol)溶解在无水DME(100ml)中,加入NBS(12.21g,69mmol),偶氮二异丁腈(0.59g,3mmol)。混合物在搅拌条件下,回流18h后,用旋转蒸发仪旋干滤液。残留物用HPLC柱制备得白色固体13-a-5(3.1g,产率:30%)。ESI-MS(M+H)+:343.7。纯度=98.2%(UV214)。1H NMR(400MHz,CDCl3)δ8.80(s,1H),8.12(d,J=6.8Hz,1H),7.36(d,J=12.0Hz,1H),4.54(s,2H),3.43(s,3H)。
化合物17-a的制备方法:
步骤a:向化合物17-a-1(4.5g,28.8mmol),对甲苯磺酸(499mg,2.9mmol)的二氯甲烷(100ml)溶液中,冷却至零摄氏度缓慢加入N-氯代丁二酰亚胺(4g,30.3mmol),搅拌2小时,室温搅拌过夜。反应结束,倒入水中,用乙酸乙酯萃取,无水硫酸钠干燥,过滤,滤液减压浓缩得到白色固体化合物17-a-2(5g)。MS m/z(ESI):189[M-H]-。
步骤b:向化合物17-a-2(5g,26.3mmol)的甲醇(130ml)溶液中逐滴加入浓硫酸(7ml,1mmol),回流搅拌5小时。反应结束,冷却至室温,倒入水中,用乙酸乙酯萃取,无水硫酸钠干燥,过滤,滤液减压浓缩,加入二氯甲烷室温搅拌20分钟,过滤得到白色固体化合物17-a(4.2g)。MS m/z(ESI):203[M-H]-。
化合物22-a的制备方法:
步骤a:以化合物17-a(2g)为原料参照实施例57中步骤3的制备方法,不同的是将反应条件换成室温搅拌过夜,得到化合物22-a-2(552mg),纯度96.57%,产率14%,MS m/z(ESI):322.1[M+H-56]+。
步骤b:以化合物22-a-2(552mg)为原料参照实施例4中步骤1的制备方法,得到化合物22-a(409mg),纯度100%,产率41%,MS m/z(ESI):288[M+H]+。
化合物25-a的制备方法:
步骤:向化合物25-a-1(2.03g,11.93mmol)的乙酸(65ml)溶液中加入溴(0.61ml,11.33mmol),室温搅拌过夜。反应结束,减压浓缩,食盐水洗,乙酸乙酯萃取,干燥分离有机相,减压浓缩得粗品,经Combi-flash柱层析纯化得到化合物25-a(3g),纯度85%,产率100%。MS m/z(ESI):249[M+H]+。
化合物36-a的制备方法:
步骤1:向50ml密封管中加入化合物36-a-1(500mg,2.23mmol),化合物36-a-2(671mg,3.35mmol),Pd2(dba)3(三(二亚苄基丙酮)二钯)(41mg,0.045mmol),BI NAP((±)-2,2’-双-(二苯膦基)-1,1’-联萘)(56mg,0.089mmol),叔丁醇钾(644mg,6.7mmol),7ml 1,4-二氧六环,90℃搅拌2h。反应结束,冷却至室温,加入30ml水和30ml乙酸乙酯,过滤,乙酸乙酯萃取,分离合并有机相,滤液减压浓缩得到粗品,经Combi-flash柱层析纯化得到黄色油状化合物36-a-3(475mg),直接用于下一步反应。MS m/z(ESI):289.1[M+H-56]+。
步骤2:将氯化氢甲醇溶液(1.5ml,5.53mmol)加入到化合物36-a-3(475mg)的甲醇溶液中,室温搅拌4小时后浓缩反应液,得化合物化合物36-a的粗品。不经纯化直接使用。
化合物37-a的制备方法:
在0℃下,用氩气保护,向化合物37-a-1(1.0g,7.09mmol)和碘(9mg,0.035mmol)的二氯甲烷混合溶液中逐滴加入液溴。滴加完毕,将反应液慢慢升至室温。在室温下避光搅拌过夜。反应用亚硫酸氢钠溶液淬灭,二氯甲烷萃取,有机相用饱和食盐水洗涤,干燥浓缩,粗品用乙醇重结晶得白色固体37-a(230mg),纯度100%,产率14.7%,MS m/z(ESI):N/A。
化合物38-a的制备方法:
在60℃下,向化合物38-a-1(2.26g,15.59mmol)和铁粉(44mg,0.78mmol)的混合溶液中逐滴加入液溴(2.49g,15.59mmol),滴加完毕,60℃继续搅拌3h。反应液冷却至室温,用亚硫酸氢钠溶液淬灭反应,用石油醚萃取,有机相用饱和食盐水洗涤,干燥浓缩,粗品经柱层析纯化(100%石油醚)得无色油状化合物38-a(2.82g),纯度75%,产率81%,MS m/z(ESI):N/A。
化合物39-a的制备方法:
在室温下,向化合物39-a-1(5g,31.06mmol),铁粉(87mg,1.55mmol)和碘(39mg,0.15mmol)的四氯化碳混合溶液中逐滴滴加液溴(5.22g,32.61mmol),滴加完毕后,反应液在室温下搅拌两天。反应液用亚硫酸氢钠溶液淬灭,用二氯甲烷萃取(2*50ml),有机相用饱和食盐水洗涤(30ml),干燥浓缩得无色油状化合物39-a(4.77g),纯度76%,产率64%,MSm/z(ESI):N/A,直接用于下一步反应中。
化合物40-a的制备方法:
将化合物40-a-1(1g,4.77mmol)的无水四氢呋喃溶液在-50℃下逐滴滴加到LDA(2M,3ml)的四氢呋喃溶液中,滴加完毕,反应液在-50℃下搅拌30分钟。在-50℃下向上述反应液中加入碘甲烷(1037mg,7.30mmol),反应液自然升至室温。反应液倒入水中,用乙酸乙酯萃取,有机相用饱和食盐水洗涤,干燥浓缩,粗品经柱层析纯化(100%石油醚)得无色油状化合物40-a(747mg),纯度77%,产率70%,MS m/z(ESI):N/A。
化合物41-a的制备方法:
将化合物41-a-1(500mg,2.5mmol)分散在5ml水中,加入1ml浓盐酸,将溶液降温至0℃。将亚硝酸钠(517mg,7.49mmol)溶解在2ml水中,在0℃下逐滴加入上述溶液中,并保持在0℃搅拌30分钟,加入氯化亚铜(990mg,10.0mmol),反应液加热至75℃,搅拌1h。反应液冷却至室温后,用乙酸乙酯萃取,有机相用饱和食盐水洗涤,干燥浓缩,粗品经柱层析纯化(100%石油醚)得无色油状化合物41-a(218mg),纯度89%,产率40%,MS m/z(ESI):N/A。
化合物42-a的制备方法:
步骤1:化合物42-a-1(200mg,0.966mmol),N-Boc-哌嗪(270mg,1.449mmol),Pd2(dba)3(44mg,0.097mmol),Johnphos(30mg,0.193mmol),叔丁醇钠(280mg,2.898mmol)的二氧六环混合溶液,在氩气保护下40℃搅拌过夜。反应液冷却至室温,用硅藻土过滤,滤液减压浓缩,粗品经柱层析纯化(PE∶EA=10∶1)得黄色油状化合物42-a-2(188mg),纯度93%,产率50%,MS m/z(ESI):257.2[M+H-56]+。
步骤2:参照中间36-a中步骤2的制备方法得到黄色固体化合物42-a(212mg)。
中间体化合物如式(I)所示,取代芳环基Ar如下表所示。
通用步骤:化合物43-a至60-a,以N-Boc-哌嗪和溴取代的芳环或溴取代的吡啶为原料,参照中间体36-a的类似方法制备。化合物58-a,参照42-a的类似方法制备。
中间体61-a的制备:
步骤a:向化合物61-a-1(2.01g,0.01mol),化合物25-a(2.49g,0.01mol),三苯基膦(5.24g,0.02mol)的四氢呋喃溶液中慢慢滴加DIAD(4.04g,0.02mol),反应液室温搅拌1h。反应液用饱和食盐水洗涤,干燥浓缩,粗品经柱层析纯化得61-a-2(2.08g),纯度100%,产率59%,MS m/z(ESI):376.1[M+H-56]+。
步骤b:向化合物61-a-2(2.08g,4.81mmol)的甲醇溶液中加入4M盐酸二氧六环溶液(5ml),反应液室温搅拌5h。反应液减压浓缩得61-a(1.6g),纯度100%,产率98%,MS m/z(ESI):370[M+H]+。
中间体62-a的制备:
步骤1:化合物62-a-1(1.0g,5.85mmol),N-Boc-哌嗪(1.3g,7.02mmol),HATU(2.22g,5.85mmol)和DIPEA(1.51g,11.7mmol)的二氯甲烷混合溶液室温搅拌16h。反应液用二氯甲烷稀释,用2N盐酸溶液、饱和食盐水洗涤,干燥浓缩,粗品经柱层析纯化(PE∶EA=7∶3)得化合物62-a-2(1.51g),纯度100%,产率76%,MS m/z(ESI):283.0[M+H]+。
步骤2:以化合物62-a-2为原料,参照36-a中步骤2的制备方法,得化合物62-a(1.21g),纯度96%,产率99%,MS m/z(ESI):239.0[M+H]+。
中间体63-a的制备:
以4-氯苯甲酸为原料,参照化合物62-a的制备方法,得化合物63-a。
实施例80:(R)-5-氯-N-(环丙基磺酰基)-2-氟-4-((1-(4-(三氟甲基)苯基)吡咯烷-2-基)甲氧基)苯甲酰胺(Z-80)的制备
步骤1:化合物80-a(9.0g,40mmol)、化合物7-a(6.08g,60mmol),(L)-脯氨酸(920mg,8mmol),碘化亚铜(764mg,4mmol)、碳酸钾(16.56g,120mmol)的二甲亚砜(50ml)混合溶液,在氩气保护下,100℃搅拌16h。反应液冷却至室温后,将反应液倒入水中,乙酸乙酯(3*60ml)萃取,有机相用水(2*150ml)和饱和食盐水(100ml)洗涤,干燥浓缩,粗品经柱层析纯化(PE/EA=4∶1)得黄色油状化合物80-b(3.98g),纯度100%,收率41%,MS m/z(ESI):246.1[M+H]+。
步骤2:向化合物80-b(956mg,3.9mmol)、化合物17-a(800mg,3.9mmol)、三苯基膦(2.04g,7.8mmol)的四氢呋喃(10ml)混合溶液中逐滴加入DIAD(1.58g,7.8mmol),室温搅拌1h。反应液减压浓缩,粗品经柱层析纯化(PE/EA=10∶1)得无色油状化合物80-c(1g),纯度80%,产率65%,MS m/z(ESI):432.2[M+H]+。
步骤3:向化合物80-c(1.1g,2.55mmol)的甲醇(20ml)溶液中加入2M氢氧化钠溶液(5ml),混合溶液60℃搅拌2h。减压除去大部分溶剂,剩余物加入20ml水,用2N盐酸溶液调PH值至3-4,用乙酸乙酯萃取,有机相用饱和食盐水洗涤,干燥浓缩得淡黄色固体化合物80-d(0.84g),纯度96%,产率79%,MS m/z(ESI):418.1[M+H]+。
步骤4:化合物80-d(100mg,0.239mmol)、环丙基磺酰胺(58mg,0.478mmol)、HATU(100mg,0.263mmol)、DIPEA(62mg,0.478mmol)、DMAP(3mg,0.024mmol)的二氯甲烷混合溶液,室温搅拌16h。反应液用20ml二氯甲烷稀释,用2N盐酸溶液和饱和食盐水洗涤,有机相干燥浓缩,粗品经Pre-HPLC纯化得白色固体化合物Z-80(12mg),纯度99%。产率10%,MS m/z(ESI):521.2[M+H]+。1H NMR(DMSO-d6,400MHz):δ7.73(d,J=7.6Hz,1H),7.42(d,J=8.8Hz,2H),7.01(d,J=12.4Hz,1H),6.78(d,J=8.8Hz,2H),4.24(br.s.,1H),4.05-4.14(m,2H),3.47(t,J=8.8Hz,1H),3.14-3.21(m,1H),2.84-2.91(m,1H),2.17-2.29(m,1H),1.99-2.07(m,3H),0.78-0.88ppm(m,4H)。
实施例119:(R)-5-氯-N-(环丙基磺酰基)-2-氟-4-((1-(6-(三氟甲基)吡啶-3-基)吡咯烷-2-基)甲氧基)苯甲酰胺(Z-119)的制备
步骤1:化合物119-a(1.13g,5mmol),化合物7-a(1.01g,10mmol),碳酸钾(1.38g,10mmol)的DMF混合溶液100℃搅拌48h。反应液冷却至室温后倒入水中,用乙酸乙酯萃取,有机相用饱和食盐水洗涤,干燥浓缩,粗品经柱层析纯化(PE∶EA=1∶1)得黄色油状化合物119-b(420mg),纯度100%,产率34%,MS m/z(ESI):247.1[M+H]+。
步骤2:以化合物119-b为原料,参照实施例80中步骤2制备方法得白色固体化合物119-c(318mg),纯度74%,产率100%,MS m/z(ESI):433.1[M+H]+。
步骤3:以化合物119-c为原料,参照实施例80中步骤3制备方法得白色固体化合物119-d(409mg),纯度95%,产率52%,MS m/z(ESI):419.1[M+H]+。
步骤4:以化合物119-d为原料,参照实施例80中步骤4制备方法得白色固体化合物Z-119(42mg),纯度100%,产率38%,MS m/z(ESI):522.1[M+H]+。1H NMR(400MHz,DMSO-d6):δ12.02(br.s.,1H),8.18(d,J=2.4Hz,1H),7.72(d,J=7.6Hz,1H),7.56(d,J=8.8Hz,1H),7.22-7.15(m,2H),4.38(d,J=8.0Hz,1H),4.20-4.17(m,2H),3.54(t,J=8.4Hz,1H),3.26-3.20(m,1H),3.06-2.99(m,1H),2.27-2.19(m,1H),2.06-2.03(m,3H),1.09-1.05(m,4H).
实施例150:(R)-5-氯-N-(环丙基磺酰基)-2-氟-4-((1-(5-(三氟甲基)吡啶-2-基)吡咯烷-2-基)甲氧基)苯甲酰胺(Z-150)的制备
步骤1:化合物22-a(6.87g,0.02mol)、化合物2-氟-5-(三氟甲基)吡啶(3.5g,0.02mol)、碳酸钾(8.29g,0.06mmol)的乙腈混合溶液80℃搅拌过夜。反应液冷却至室温后,加水,用乙酸乙酯萃取,有机相干燥浓缩,粗品经柱层析纯化(PE/EA=10∶1)得淡黄色固体化合物150-a(6.9g),纯度93%,产率75%,MS m/z(ESI):433.1[M+H]+。
步骤2:以化合物150-a为原料,参照实施例80中步骤3制备方法得白色固体化合物150-b(6.422),纯度99%,产率92%,MS m/z(ESI):419.1[M+H]+。
步骤3:以化合物150-b为原料,参照实施例80中步骤4制备方法得白色固体化合物Z-150(4.73g),纯度100%,产率59%,MS m/z(ESI):522.1[M+H]+。1H NMR(400MHz,DMSO-d6):δ12.01(br.s.,1H),8.38(br.s.,1H),7.77(dd,J=2.4Hz,8.8Hz,1H),7.73(d,J=7.6Hz,1H),7.38(d,J=12.4Hz,1H),6.68(d,J=9.2Hz,1H),4.54-4.51(m,1H),4.30(dd,J=3.2Hz,10.0Hz,1H),4.18(dd,J=6.0Hz,9.6Hz,1H),3.54(t,J=8.4Hz,1H),3.37-3.30(m,1H),3.08-3.00(m,1H),2.31-2.18(m,1H),2.10-1.99(m,3H),1.12-1.07(m,4H).
实施例125:(R)-5-环丙基-N-(环丙基)-2-氟-4-((1-(4-(三氟甲基)苯基)吡咯烷-2-基)甲氧基)苯甲酰胺(Z-125)的制备
步骤1:4-溴-三氟甲基苯(20g,0.089mol),化合物7-a(13.486g,0.133mol),(L)-脯氨酸(2.047g,0.017mol),碘化亚铜(1.693g,0.009mol)和碳酸钾(30.854g,0.267mol)的二甲亚砜混合溶液在氩气保护下,90℃搅拌过夜,反应液冷却至室温后倒入水中,乙酸乙酯萃取,有机相用饱和食盐水洗涤,干燥浓缩,粗品经柱层析纯化(PE∶EA=3∶1)得黄色油状化合物125-b(8.872g),纯度100%,产率41%,MS m/z(ESI):246.1[M+H]+。
步骤2:向化合物125-b(1.48g,6.02mmol),化合物25-a(1.5g,6.02mmol),三苯基膦(3.15g,12.04mmol)的四氢呋喃溶液中逐滴加入DIAD(2.43g,12.04mmol),滴加完毕,反应液在室温下继续搅拌1h。反应液减压浓缩,粗品经柱层析纯化后(PE∶EA=10∶1),用10ml甲醇打浆,过滤,滤饼用甲醇洗涤,干燥得白色固体化合物125-c(1.24g),纯度98%,产率43%,MS m/z(ESI):478.1[M+H]+。
步骤3:化合物125-c(1.13g,2.6mmol),环丙基硼酸(0.45g,5.2mmol),Pd(dppf)Cl2(0.19g,0.26mmol),碳酸铯(1.7g,5.2mmol)的二氧六环溶液在氩气保护下,90℃搅拌24h。反应液冷却至室温后过滤,滤饼用乙酸乙酯洗涤,滤液减压浓缩,粗品经柱层析纯化(PE∶EA=10∶1)得白色固体化合物125-d(1.13g),纯度100%,产率99%,MS m/z(ESI):438.2[M+H]+。
步骤4:向化合物125-d(1.053g,2.407mmol)的甲醇溶液中加入1M氢氧化钠溶液(10ml),反应液在60℃下搅拌2h。反应液减压浓缩除去甲醇,加水,用1M盐酸溶液调PH值至2-3,过滤,滤饼用水洗涤,干燥,得白色固体125-e(1.16g),纯度100%,产率100%,MS m/z(ESI):424.1[M+H]+。
步骤5:化合物125-e(200mg,0.472mmol),环丙基磺酰胺(290mg,2.362mmol),EDCI(270mg,1.417mmol),DMAP(170mg,1.417mmol),DIPEA(370mg,2.834mmol)的二氯甲烷混合溶液室温搅拌过夜。反应液用水洗涤,干燥浓缩,粗品经Pre-HPLC纯化得白色固体化合物Z-125(72mg),纯度100%,产率29%,MS m/z(ESI):527[M+H]+。1H NMR(500MHz,DMSO):δ11.815(s,1H),7.453(d,J=10.5Hz,2H),7.110(d,J=10.5Hz,1H),6.956(d,J=16Hz,1H),6.819(m,J=11Hz,2H),4.341-4.321(m,1H),4.114-4.087(m,2H),3.514(t,J=11Hz,1H),3.226-3.208(m,1H),3.069-3.057(m,1H),2.216-1.923(m,5H),1.117-1.079(m,4H),0.882-0.763(m,2H),0.657-0.644(m,2H).
实施例142:(R)-5-环丙基-N-(环丙基磺酰基)-2-氟-4-((1-(5-(三氟甲基)吡啶-2-基)吡咯烷-2-基)甲氧基)苯甲酰胺(Z-142)的制备
步骤1:化合物61-a(1.6g,4.34mmol),2-氟-5-三氟甲基吡啶(0.72g,4.34mmol),碳酸钾(1.8g,13.02mmol)的乙腈混合溶液80℃搅拌20h。反应液冷却至室温,用乙酸乙酯稀释,用水、饱和食盐水洗涤,有机相干燥浓缩,粗品用甲醇打浆,过滤,滤饼用甲醇洗涤,干燥得白色固体化合物142-a(1.1g),纯度100%,产率53%,MS m/z(ESI):479.1[M+H]+。
步骤2:以化合物142-a(1.0g,2.1mmol)为原料,参照实施例125中步骤3制备方法得白色固体化合物142-b(0.9g),纯度95%,产率98%,MS m/z(ESI):439.2[M+H]+。
步骤3:以化合物142-b(0.9g,2.05mmol)为原料,参照实施例125中步骤4制备方法得白色固体化合物142-c(0.8g),纯度96%,产率92%,MS m/z(ESI):425.2[M+H]+。
步骤4:以化合物142-c(100mg,0.236mmol)为原料,参照实施例125中步骤5制备方法得白色固体化合物Z-142(26mg),纯度100%,产率24%,MS m/z(ESI):528.2[M+H]+。1HNMR(DMSO-d6,400MHz):δ11.79(br.s.,1H),8.38(s,1H),7.77(dd,J=8.8,2.4Hz,1H),7.11(d,J=8.4Hz,1H),7.04(d,J=13.2Hz,1H),6.68(d,J=9.2Hz,1H),4.54(br.s.,1H),4.23(dd,J=9.6,3.6Hz,1H),4.07(dd,J=9.8,6.8Hz,1H),3.54(t,J=9.2Hz,1H),3.32-3.41(m,1H),2.92-3.07(m,1H),2.11-2.27(m,1H),1.88-2.09(m,4H),0.95-1.08(m,4H),0.74-0.91(m,2H),0.61ppm(dd,J=5.2,1.6Hz,2H).
实施例89:5-氯-N-(环丙基磺酰基)-4-((4-(3,4-二氯苯基)哌嗪-1-基)甲基)-2-氟苯甲酰胺(Z-89)的制备
步骤1:以化合物13-a-3(300mg)为原料参照实施例125中步骤5的制备方法,得到化合物89-c(456mg),MS m/z(ESI):290[M-H]-。
步骤2:以化合物89-c(452mg)为原料参照中间体13-a中步骤d的制备方法,得到化合物89-d(419mg),MS m/z(ESI):372[M+H]+。
步骤3:化合物89-d(109mg)、化合物10-a、碳酸钾的乙腈混合溶液80℃搅拌3h。反应液冷却至室温,加水,乙酸乙酯萃取,有机相干燥浓缩,粗品经Pre-HPLC纯化得到化合物Z-89(23.34mg),纯度100%,产率15%,MS m/z(ESI):520.1[M+H]+。1H NMR(400MHz,DMSO-d6):δ7.71(d,J=6.4Hz,1H),7.40(d,J=11.2Hz,1H),7.36(d,J=9.2Hz,1H),7.10(d,J=2.8Hz,1H),6.90(dd,J=3.2Hz,9.2Hz,1H),3.63(s,2H),3.20-3.18(m,4H),3.12-2.94(m,1H),2.56-2.55(m,4H),1.03-0.96(m,4H).
实施例92、159、164:
化合物Z-92、Z-159、Z-164以89-d为原料与相应的苯基取代的或吡啶基取代的哌嗪参照实施例89中步骤3相似的方法制备。
实施例117:5-氯-N-(环丙基磺酰基)-4-((1-(3,4-二氯苯基)哌啶-4-基)氧基)-2-氟苯甲酰胺(Z-117)的制备
步骤1:4-溴-1,2-二氯苯(200g,0.885mol)、化合物117-a(224g,2.218mol)、(L)-脯氨酸(10.2g,0.089mol),碘化亚铜(34.2g,0.180mol)和碳酸钾(366g,2.652mol)的二甲亚砜(1.0L)混合溶液在氩气保护下,100℃搅拌16h。反应液冷却至室温,加入2.0L乙酸乙酯,过滤除去不溶的物质,滤饼用乙酸乙酯洗涤,滤液用饱和食盐水洗涤,干燥浓缩,得到化合物117-b(175g)的粗品,纯度88%,MS m/z(ESI):247[M+H]+。
步骤2:在0℃下,向化合物117-b(4.7g,16.26mmol),化合物17-a(3.34g,16.26mmol),三苯基膦(8.52g,32.52mmol)的四氢呋喃(20ml)溶液中逐滴加入DIAD(6.5g,32.52mmol),反应液在氮气保护下室温搅拌12h。反应液倒入水中,用乙酸乙酯萃取,有机相用饱和食盐水洗涤,干燥浓缩,得化合物117-c(6.7g)的粗品,纯度89%,MSm/z(ESI):432[M+H]+。
步骤3:向化合物117-c(6.7g,15.5mmol)的四氢呋喃溶液中加入4M氢氧化钠溶液(15ml),反应液室温搅拌过夜。减压浓缩除去四氢呋喃,用1M盐酸溶液将PH值调至5-6,用乙酸乙酯萃取,有机相用饱和食盐水洗涤,干燥浓缩得到化合物117-d(6.4g)的粗品,纯度90%,MS m/z(ESI):419[M+H]+。
步骤4:化合物117-d(100mg,0.239mmol)、环丙基磺酰胺(58mg,0.478mmol)、HATU(100mg,0.263mmol)、三乙胺(48mg,0.478mmol)、DMAP(3mg,0.024mmol)的二氯甲烷溶液室温搅拌12h。反应液加入20ml二氯甲烷稀释,用2N盐酸溶液洗涤,有机相干燥浓缩,粗品经Pre-HPLC纯化得化合物Z-117(15mg),纯度100%,产率12%,MS m/z(ESI):523.1[M+H]+。1HNMR(DMSO-d6,400MHz):δ11.99(br.s.,1H),7.74(d,J=7.6Hz,1H),7.29-7.45(m,2H),7.14(d,J=2.8Hz,1H),6.94(dd,J=9.2,2.8Hz,1H),4.78-4.93(m,1H),3.39-3.54(m,2H),3.13-3.26(m,2H),2.96-3.10(m,1H),1.90-2.07(m,2H),1.61-1.78(m,2H),0.94-1.22ppm(m,4H).
实施例172:(R)-5-氯-N-(环丙基磺酰基)-4-((4-(3,4-二氯苯基)-2-甲基哌嗪-1-基)甲基)-2-氟苯甲酰胺(Z-172)的制备
化合物36-a(100mg,0.408mmol),化合物89-d(151mg,0.408mmol)和碳酸钾的DMF混合溶液,80℃搅拌3h。反应液冷却至室温,将反应液倒入水中,用乙酸乙酯萃取,有机相用饱和食盐水洗涤,干燥浓缩,粗品经Pre-HPLC纯化得白色固体化合物Z-172(70mg),纯度100%,产率32%,MS m/z(ESI):533.8[M+H]+。1H NMR(dmso,400MHz):δ12.18(brs.,1H),7.71(d,J=6.0Hz,1H),7.49(d,J=11.2Hz,1H),7.35(d,J=9.2Hz,1H),7.11(d,J=2.8Hz,1H),6.91(dd,J=8.8,2.8Hz,1H),3.97(d,J=14.8Hz,1H),3.54(d,J=8.4Hz,1H),3.35-3.50(m,2H),2.96-3.09(m,1H),2.86(t,J=10.4Hz,1H),2.57-2.77(m,3H),2.36(br.s.,1H),0.97-1.17ppm(m,7H)
实施例173-188:
化合物Z-173至Z-188以化合物89-d为起始原料,参照实施例172的方法进行制备,不同的是将36-a换成相应的取代的溴苯。
实施例189:N-(环丙基磺酰基)-5-乙基-2-氟-4-((4-(4-(三氟甲氧基)苯基)哌嗪-1-基)甲基)苯甲酰胺(Z-189)的制备
步骤1:以化合物87-b为原料,参照实施例89中步骤1制备方法,得到化合物189-a。
步骤2:以化合物189-a为原料,参照实施例89中步骤2制备方法,得到化合物189-b。
步骤3:以化合物189-b为原料,参照实施例89中步骤3制备方法,得到化合物189-c。
步骤4:化合物189-c、乙烯基三氟硼酸钾、Pd(dppf)Cl2,三乙胺的乙醇混合溶液在氩气保护下,90℃搅拌6h。反应液冷却至室温,用硅藻土过滤,滤液浓缩,得到189-d粗品,直接用于下一步反应。
步骤5:向化合物189-d的甲醇溶液中,加入钯/炭,反应液在氢气氛围下室温搅拌过夜。反应液用硅藻土过滤,滤液减压浓缩,经Pre-HPLC纯化得白色固体化合物Z-189(39.12mg),纯度100%,产率10%,MS m/z(ESI):529.9[M+H]+。1H NMR(400MHz,DMSO-d6):δ12.01(br.s.,1H),7.48(d,J=7.2Hz,1H),7.28(d,J=11.6Hz,1H),7.19(d,J=8.8Hz,2H),7.00(d,J=9.2Hz,2H),3.59(s,2H),3.20-3.16(m,4H),3.11-3.05(m,1H),2.70(q,J=7.6Hz,2H),2.60-2.56(m,4H),1.18(t,J=7.6Hz,3H),1.13-1.08(m,4H).
实施例190-193:
化合物Z-190至Z-193以化合物189-b为原料,参照实施例189中步骤3-5制备方法,不同的是Z-191至Z-193的制备中,将步骤5中的钯炭换成二氧化铂。
实施例194:N-(环丙基磺酰基)-5-乙基-2-氟-4-((4-(5-(三氟甲氧基)吡啶-2-基)哌嗪-1-基)甲基)苯甲酰胺(Z-194)的制备
步骤1:以化合物57-a为原料,参照实施例189中步骤3制备方法,得化合物194-a。
步骤2:以化合物194-a为原料,参照实施例189中步骤4制备方法,得化合物194-b。
步骤3:以化合物194-b为原料,参照实施例189中步骤5制备方法,得化合物Z-194
513.2[M+H]+。1H NMR(400MHz,DMSO-d6):δ12.02(s,1H),8.15(d,J=2.4Hz,1H),7.60(dd,J1=9.2Hz,J2=2.0Hz,1H),7.48(d,J=7.2Hz,1H),7.29(d,J=11.6Hz,1H),6.91(d,J=9.2Hz,1H),3.58(s,2H),3.53(m,4H),3.04-3.11(m,1H),2.67-2.73(q,J=7.2Hz,2H),2.49-2.50(m,4H),1.18(t,J=7.6Hz,3H),1.09-1.12(m,4H).
实施例195:(R)-N-(环丙基)-2-氟-5-甲基-4-((1-(5-(三氟甲基)吡啶-2-基)吡咯烷-2-基)甲氧基)苯甲酰胺(Z-195)的制备
步骤1:以化合物142-a(520mg,1.09mmol)为原料,参照实施例125中步骤3制备方法,不同的是将环丙基硼酸换成甲基硼酸,得白色固体化合物195-b(440mg),纯度100%,产率98%,MS m/z(ESI):413.2[M+H]+。
步骤2:以化合物195-b(440mg,1.07mmol)为原料,参照实施例125中步骤4制备方法得白色固体化合物195-c(420mg),纯度92%,产率98%,MS m/z(ESI):399.2[M+H]+。
步骤3:以化合物195-c(100mg,0.25mmol)为原料,参照实施例125中步骤5制备方法得白色固体化合物Z-195(25.75mg),纯度100%,产率21%,MS m/z(ESI):N/A。1H NMR(DMSO-d6,400MHz):δ11.78(br.s.,1H),8.38(s,1H),7.77(dd,J=9.2,2.4Hz,1H),7.46(d,J=8.4Hz,1H),7.07(d,J=12.8Hz,1H),6.68(d,J=9.2Hz,1H),4.51(br.s.,1H),4.14-4.28(m,1H),4.01-4.06(m,1H),3.48-3.61(m,1H),3.30-3.39(m,1H),2.96-3.06(m,1H),1.91-2.21(m,7H),0.94-1.15ppm(m,4H)。
实施例196:(环丙基磺酰基)-4-((4-(3,4-二氯苯基)哌嗪-1-基)甲基)-2-氟苯甲酰胺(Z-196)的制备
步骤1:以化合物189-b为原料,参照实施例89中步骤3制备方法,得化合物196-a。
步骤2:以化合物196-a为原料,参照实施例125中步骤3制备方法,得化合物Z-196。
MS m/z(ESI):NA。1H NMR(400MHz,DMSO-d6):δ11.96(br.s.,1H),7.36(d,J=8.8Hz,1H),7.27(d,J=11.6Hz,1H),7.20(d,J=6.8Hz,1H),7.10(d,J=2.8Hz,1H),6.90(dd,J=2.8,8.8Hz,1H),3.73(s,2H),3.22-3.18(m,4H),3.07-3.02(m,1H),2.58-2.54(m,4H),2.10-2.02(m,1H),1.10-1.06(m,4H),0.94-0.88(m,2H),0.68-0.63(m,2H).
实施例197:(环丙基磺酰基)-4-((4-(3,5-二氯苯基)哌嗪-1-基)甲基)-2-氟苯甲酰胺(Z-197)的制备
步骤1:以化合物189-b为原料,参照实施例89中步骤3制备方法,不同的是将化合物10-a换成化合物59-a,得化合物197-a。
步骤2:以化合物197-a为原料,参照实施例125中步骤3制备方法,得化合物Z-197
MS m/z(ESI):NA。1H NMR(400MHz,DMSO-d6):δ12.03(br.s.,1H),7.26-7.22(m,2H),6.94(d,J=1.6Hz,2H),6.86(t,J=1.6Hz,1H),3.71(s,2H),3.27-3.24(m,4H),3.05-3.00(m,1H),2.57-2.53(m,4H),2.10-2.05(m,1H),1.05-0.97(m,4H),0.96-0.91(m,2H),0.67-0.63(m,2H).
对比例1:5-(环丙基磺酰基)-4-((4-(3,5-二氯苄基)哌嗪-1-基)甲基)-2-氟苯甲酰胺(C1)的制备
步骤1:化合物1-1(1.96g,10.0mmol),N-Boc-哌嗪(1.95g,10.5mmol),碳酸钾(2.76g,20.0mmol)的乙腈(20ml)混合溶液,80℃搅拌16h。反应液冷却至室温,减压除去溶剂后,加水,用乙酸乙酯(2*50ml)萃取,有机相用饱和食盐水(30ml)洗涤,干燥分离有机相,滤液减压浓缩得到黄色油状化合物1-2(3.5g),纯度90.26%,产率100%。MS m/z(ESI):345.0[M+H]+。
步骤2:化合物1-2的甲醇(50ml)溶液中加入盐酸二氧六环溶液(10ml,40.58mmol),混合物室温搅拌16h,减压浓缩得到黄色固体化合物1-3(2.9g),纯度91.49%,产率100%。MS m/z(ESI):245.0[M+H]+。
步骤3:化合物1-3(2.9g,10.28mmol),化合物1-4(3.35g,10.28mmol),碳酸钾(2.84g,20.56mmol)的乙腈(50ml)混合溶液,80℃搅拌16h。反应液冷却至室温,减压除去溶剂后,加水,用乙酸乙酯(2*50ml)萃取,有机相用饱和食盐水(30ml)洗涤,干燥分离有机相,滤液减压浓缩得到粗品,经柱层析纯化得到黄色油状化合物1-5(2.6g),纯度100%,产率51.7%,MS m/z(ESI):491.0[M+H]+。
步骤4:化合物1-5(1.0g,2.04mmol),环丙基硼酸(0.35g,4.08mmol),Pd(dppf)Cl2(149mg,0.204mmol),碳酸铯(1.33g,4.08mmol)的二氧六环(10ml)溶液,在氩气保护下,80℃搅拌16h。反应液冷却至室温,过滤除去固体,滤饼用乙酸乙酯洗涤,滤液减压浓缩,经柱层析纯化得到无色油状化合物1-6(130mg),纯度97.42%。产率14.1%,MS m/z(ESI):451.0[M+H]+。
步骤5:向化合物1-6(130mg,0.265mmol)的甲醇(10ml)溶液中加入氢氧化钠溶液(5M,2ml),混合物在60℃搅拌2h。减压除去大部分溶剂,剩余物加水溶解,用1N盐酸溶液调PH值至7左右,用乙酸乙酯萃取(2*10ml),有机相用饱和食盐水洗涤(10ml),有机相干燥浓缩得到无色油状化合物1-7(110mg),纯度97.7%,产率94.8%,MS m/z(ESI):437.0[M+H]+。
步骤6:化合物1-7(110mg,0.252mmol),环丙基磺酰胺(46mg,0.378mmol),EDCI(97mg,0.504mmol),DMAP(31mg,0.252mmol),DIPEA(98mg,0.756mmol)的二氯甲烷(5ml)混合溶液室温搅拌20h。反应液用二氯甲烷稀释,用水、饱和食盐水洗涤,有机相干燥浓缩后经pre-HPLC纯化后得到白色固体化合物C1(35mg),纯度100%,产率25.7%,MS m/z(ESI):540.1[M+H]+。1H NMR(dmso,400MHz):δ12.10(br.s.,1H),7.66(br.s.,1H),7.52(br.s.,2H),7.34(d,J=10.8Hz,1H),7.21(d,J=7.2Hz,1H),4.13(br.s.,4H),2.84-3.32(m,9H),2.01-2.12(m,1H),1.04-1.15(m,4H),0.87-0.97(m,2H),0.65-0.72ppm(m,2H)
对比例2、11
化合物C2以3,4-二氯苄溴为原料,参照对比例1的制备方法进行制备,不同的是将步骤6中的环丙基磺酰胺换成甲基磺酰胺。
化合物C11参照对比例1的制备方法进行制备,不同的是将步骤6中环丙基磺酰胺换成甲基磺酰胺。
对比例4:5-氯-4-((4-(4-氯-3-甲基苄基)哌嗪-1-基)甲基)-N-(环丙基磺酰基)-2-氟苯甲酰胺(C4)的制备
步骤1:向化合物3-1(1g,5.85mmol)的四氢呋喃溶液中逐滴加入硼烷四氢呋喃溶液(1M,5.9ml),反应液室温搅拌16h。向反应液中逐滴加入甲醇淬灭反应,减压浓缩,粗品经柱层析纯化(PE∶EA=7∶3)得淡黄色固体化合物4-1(910mg),纯度100%,产率99%,MS m/z(ESI):N/A。
步骤2:向化合物4-1(650mg,4.14mmol)和DIPEA(1.07g,8.28mmol)的二氯甲烷混合溶液中逐滴加入甲基磺酰氯(524mg,4.55mmol)的二氯甲烷溶液,反应液室温搅拌16h。反应液用2N盐酸溶液和饱和食盐水洗涤,干燥浓缩得棕色油状化合物4-2(780mg),纯度97%,产率80%,MS m/z(ESI):N/A。
步骤3:以化合物4-2为原料,参照对比例1中步骤1制备方法得黄色油状化合物4-3(950mg),纯度100%,产率88%,MS m/z(ESI):325.0[M+H]+。
步骤4:以化合物4-3为原料,参照对比例1中步骤2制备方法得白色固体化合物4-4(750mg),纯度100%,产率95%,MS m/z(ESI):225.0[M+H]+。
步骤5:以化合物4-4为原料,参照对比例1中步骤3制备方法得白色固体化合物C4(140mg),纯度100%,产率70%,MS m/z(ESI):513.8[M+H]+。1H NMR(dmso,400MHz):δ12.32(br.s.,1H),9.79(br.s.,1H),7.74(d,J=6.4Hz,1H),7.40-7.55(m,3H),7.32(d,J=8.0Hz,1H),4.26(br.s.,2H),3.94(br.s.,4H),3.69(br.s.,2H),3.26(br.s.,2H),2.97-3.18(m,1H),2.92(br.s.,2H),2.33(s,3H),1.03-1.18ppm(m,4H).
对比例3、5、6、12、13
化合物C3、C5分别以62-a和63-a为原料,参照对比4中步骤5制备方法进行制备。
化合物C6以4-氯苯甲酸为原料,参照对比4的制备方法进行制备。
化合物C12、C13以相应的苯基取代的哌嗪为原料,参照对比例4中步骤5的制备方法,不同的是将化合物89-d换成13-a。
对比例7:(R)-5-氯-4-((1-(4-氯苄基)吡咯烷-2-基)甲氧基)-N-(环丙基磺酰基)(C7)的制备
步骤1:化合物22-a(75mg,0.463mmol),化合物7-1(150mg,0.463mmol),碳酸钾(192mg,1.388mmol)的乙腈混合溶液,80℃搅拌3h。反应液冷却至室温后,反应液倒入水中,用乙酸乙酯萃取,有机相干燥浓缩得黄色油状化合物7-2(165mg),纯度84.4%,产率87%,MS m/z(ESI):412.2[M+H]+。
步骤2:向化合物7-2的甲醇溶液中加入氢氧化钠溶液(2M,0.8ml),混合物室温搅拌3h。反应液减压浓缩,剩余物用水溶解后用1M盐酸溶液调节PH至1-2,过滤,滤饼用水洗涤,干燥得白色固体化合物7-3(121mg),纯度95.33%,产率76%,MS m/z(ESI):398.1[M+H]+。
步骤3:以化合物7-3为原料,参照对比例2中步骤6的制备方法得白色固体化合物C7(19mg),MS m/z(ESI):500.9[M+H]+。1H NMR(400MHz,DMSO-d6):δ12.06(br.s.,1H),7.81(d,J=7.2Hz,1H),7.57-7.51(m,4H),7.29(d,J=12.0Hz,1H),4.72-4.68(m,1H),4.49-4.45(m,1H),4.40-4.35(m,2H),4.08(br.s.,1H),3.26-3.23(m,2H),3.08-3.03(m,1H),2.31-2.26(m,1H),2.04(br.s.,1H),1.94-1.79(m,2H),1.13-1.08(m,4H).
对比例8:(R)-5-氯-N-(环丙基磺酰基)-2-氟-4-((1-(4-(三氟甲基)苄基)吡咯烷-2-基)甲氧基)(C8)的制备
以化合物8-1为原料,参照对比例7制备方法得白色固体化合物C8(48mg),MS m/z(ESI):534.9[M+H]+。1H NMR(400MHz,DMSO-d6):δ12.09(br.s.,1H),7.84-7.74(m,5H),7.30(d,J=12.0Hz,1H),4.80-4.77(m,1H),4.50-4.38(m,3H),4.10-4.08(m,1H),3.26-3.24(m,2H),3.09-3.02(m,1H),2.32-2.29(m,1H),2.05-2.03(m,1H),1.92-1.80(m,2H),1.13-1.08(m,4H).
对比例9:(R)-5-氯-4-((1-(4-氯苯甲酰基)吡咯烷-2-基)甲氧基)-N-(环丙基磺酰基)(C9)的制备
步骤1:化合物9-1(100mg,0.639mmol)的二氯亚砜(2ml)溶液,80℃搅拌3h。反应液冷却至室温,减压浓缩除去溶剂。剩余物用二氯甲烷(10ml)溶解,加入化合物22-a(207mg,0.639mmol),三乙胺(291mg,1.916mmol),反应液室温搅拌4h。反应液用1M的盐酸和饱和食盐水洗涤,有机相干燥浓缩得黄色油状化合物9-2(228mg),纯度92.16%,产率84%,MS m/z(ESI):426.1[M+H]+。
步骤2:以化合物9-2(228mg,0.535mmol)为原料,参照对比例7中步骤2制备方法得白色固体化合物9-3(178mg),MS m/z(ESI):412.0[M+H]+。
步骤3:以化合物9-3(100mg,0.242mmol)为原料,参照对比例2中步骤6制备方法得到白色固体化合物C9(23mg),MS m/z(ESI):515.0[M+H]+。1H NMR(400MHz,DMSO-d6):δ12.05(br.s.,1H),7.78(d,J=7.2Hz,1H),7.52-7.46(m,4H),7.37(d,J=12.4Hz,1H),4.48-4.46(m,1H),4.38-4.37(m,2H),3.42-3.35(m,2H),3.09-3.04(m,1H),2.17-2.09(m,1H),2.03-1.95(m,2H),1.80-1.74(m,1H),1.14-1.10(m,4H).
对比例10:(R)-5-氯-N-(环丙基磺酰基)-2-氟-4-((1-(4-(三氟甲基)苯甲酰基)吡咯烷-2-基)甲氧基)(C10)的制备
以化合物10-1(110mg,0.247mmol)为原料,参照对比例9制备方法得白色固体化合物C10(13mg),MS m/z(ESI):549.0[M+H]+。1H NMR(400MHz,DMSO-d6):δ12.04(br.s.,1H),7.81-7.75(m,3H),7.65-7.62(m,2H),7.36(d,J=12.8Hz,1H),4.48-4.46(m,1H),4.39-4.37(m,2H),3.48-3.44(m,2H),3.06-3.03(m,1H),2.14-2.11(m,1H),2.01-1.96(m,2H),1.80-1.75(m,1H),1.12-1.08(m,4H).
测试例1:钠离子(hNav1.7、hNav1.5和hNaV1.8)和钙离子(hCav3.2)通道的手动膜片钳实验
hNav1.7、hNav1.5手动膜片钳实验:
膜片电压钳电生理学可以直接测量并定量电压门控钠通道(各种Nav)的电流阻断并可以测定阻断的时间和电压依赖,其已被解释为对钠通道的静息、开放和失活状态的结合差异来反映化合物的抑制或激活效应(Hille,B.,Journal of General Physiology(1977),69:497-515)。
本发明代表性的化合物采用手动膜片钳实验进行,本研究的目的是应用手动膜片钳的方法在转染特定离子通道的稳定细胞株上测试化合物对该离子通道电流的作用。其使用的稳定细胞株CHO-hNav1.7和HEK-hNav1.5分别来自Genionics公司和WuXi Apptec(上海)公司。
手动膜片钳实验方案如下:
(一)溶液及化合物的配制:采用全细胞膜片钳技术记录hNav1.7和hNav1.5电流。实验中,细胞外液的组成成分(mM):HEPES:5,NaCl:40,KCl:3,CaCl2:1,MgCl2:1,CdCl2:0.1,TEA-Cl:20。用NaOH调节pH值至7.3,同时用蔗糖调节渗透压至310-320mOsm,过滤后4℃保存。细胞内液的组成成分(mM):HEPES:10,NaCl:10,CsOH:5,CsF:140,EGTA:1。用CsOH调节pH值至7.3,同时用蔗糖调节渗透压至280-290mOsm,过滤后-20℃保存。
阳性对照药和待测化合物先溶于100%DMSO(Sigma-Aldrich,D2650,配置成一定浓度(100nM,1000nM)的储备溶液。实验前用DMSO将上述储备溶液进行系列稀释,然后再用细胞外液进一步稀释得到所需浓度的测试溶液。细胞外液中DMSO最终浓度不超过0.30%。
(二)手动膜片钳实验:取细胞悬液加于35mm的培养皿中,置于倒置显微镜载物台上。待细胞贴壁后,用细胞外液灌流,流速为1-2mL/min。玻璃微电极由微电极拉制仪两步拉制,其入水电阻值为2-5MΩ。通过Digidata 1440(Molecular Devices)和pCLAMP软件(10.2版,Molecular Devices)A/D-D/A数模转换,进行刺激发放及信号采集;膜片钳放大器(Multiclamp 700B,Molecular Devices)放大信号,滤波为4KHz。
在hNav1.7和hNav1.5手动膜片钳实验中运用两种不同的电压刺激程序。
一种是失活刺激程序,钳制电位设置在相对应通道的V1/2,即大约50%的通道处于失活状态。接着给予电压至-120mV,持续50ms。然后去极化至-10mV,持续20ms引出钠电流,最后回到钳制电位。这种刺激程序也可以称之为通道状态依赖的电压刺激程序。
另一种是非失活刺激程序,保持钳制电位在-120mV,给予电压刺激至-10mV,持续20ms引出钠电流,最后回到钳制电位。也就是说在该种刺激程序条件下,所有的通道都没有经历过失活状态,而是直接从静息状态进行激活。
上述两种电压刺激程序的时间间隔均为10s。化合物的抑制效应通过加药前后的电流变化来进行计算,而IC50数值由Hill方程进行拟合所得。如果化合物在上述两种不同的电压刺激下显示出对通道效应有一定倍数的差异,那么该化合物对该通道是具有状态依赖性的。结果见表1。
hNav1.8手动膜片钳实验
重组HEK293细胞系稳定表达人电压门控钠通道亚型1.8(hNaV1.8).cDNA严格遵循GenBank序列号:NM_014191.2。稳定表达钠通道的HEK293或CHO细胞系在含有10%胎牛血清及0.8mg/mL G418的F12/DMEM培养基中培养,培养温度为37℃,二氧化碳浓度为5%。细胞外液:140mM NaCl,4mM KCl,1mM MgCl2,2mM CaCl2,5mM D-Glucose monohydrate,10mMHEPES,pH=7.4 with NaOH。电极内液:145 CsCl,0.1 CaCl2,2 MgCl2,10NaCl,0.5 Na2-GTP(鸟苷三磷酸二钠盐),2 Mg-ATP(腺嘌呤核甘三磷酸镁盐),1.1 EGTA(乙二醇双(2-氨基乙基醚)四乙酸),10HEPES(4-羟乙基哌嗪乙磺酸),pH 7.2 with CsOH。
用微电极拉制仪(P97,Sutter Instruments)将毛细玻璃管(BF150-86-10,SutterInstruments)拉制成记录电极。在倒置显微镜(IX71,Olympus)下操纵微电极操纵仪(MP285,Sutter Instruments)将记录电极接触到细胞上,给予负压抽吸,形成GΩ封接。形成GΩ封接后进行快速电容补偿,然后继续给予负压,吸破细胞膜,形成全细胞记录模式。然后进行慢速电容的补偿并记录膜电容及串联电阻。不给予漏电补偿。记录钠电流,数据由EPC-10放大器(HEKA)进行采集并储存于PatchMaster(HEKA)软件中。
当全细胞记录的钠电流稳定后开始顺序给药,每个药物测试5-6个浓度,每个药物浓度作用至5分钟或达到稳态后检测下一个浓度,每个细胞以其自身为对照。每个浓度至少独立重复检测3个细胞。所有电生理实验均在室温下进行。
钠电流电压刺激方案如下:当形成全细胞封接后细胞膜电压钳制于-90mV,去极化电压阶跃从-90mV除极至-10mV维持40ms,每隔10秒重复采集数据,观察药物对钠电流的作用。
首先将每一个浓度作用下的电流与给药前电流进行标准化并计算每一个药物浓度对应的抑制率(1-(待测化合物电流峰值)/(对照组电流峰值))。对每一个浓度计算平均数和标准误,并用以下的方程计算每种化合物的半抑制浓度。抑制率=1/(1+(IC50/C)h)
用以上方程对剂量依赖效应进行非线性拟合,其中C代表药物浓度,IC50为的半抑制浓度,h代表希尔系数。
hCav3.2通道的手动膜片钳实验:
用于手动膜片钳实验的稳定细胞株HEK-hCav3.2来自于WuXi Apptec(上海)公司。
溶液及化合物的配制:采用全细胞膜片钳技术记录hCav3.2电流。实验中细胞外液的组成成分(毫摩尔):HEPES 10,CsCl 6,CaCl2 2,TEA-Cl 140。用CsOH调节pH值至7.4,同时用蔗糖调节渗透压至310-320mOsm,过滤后4℃保存。细胞内液的的组成成分(毫摩尔):HEPES 10,CsCl 55,CsSO4 75,MgCl2 10,EGTA 0.1。用CsOH调节pH值至7.2,同时用蔗糖调节渗透压至280-290mOsm,过滤后-20℃保存。阳性对照药和待检测的化合物先溶于100%DMSO(Sigma-Aldrich,D2650,配置成一定浓度的储备溶液。实验前用DMSO将上述储备溶液进行系列稀释,然后再用细胞外液进一步稀释得到所需浓度的测试溶液。细胞外液中DMSO最终浓度不超过0.30%。
手动膜片钳实验:取细胞悬液加于35mm的培养皿中,置于倒置显微镜载物台上。待细胞贴壁后,用细胞外液灌流,流速为1-2mL/min。玻璃微电极由微电极拉制仪两步拉制,其入水电阻值为2-5MΩ。通过Digidata 1440(Molecular Devices)和pCLAMP软件(10.2版,Molecular Devices)A/D-D/A数模转换,进行刺激发放及信号采集;膜片钳放大器(Multiclamp 700B,Molecular Devices)放大信号,滤波为4KHz。下面的电压刺激程序运用到hCav 3.2手动膜片钳实验中,即钳制电位设置在-110mV,给予-85mV脉冲电压持续500ms,然后再去极化至-40mV持续50ms引出hCav3.2钙通道电流,最后回到钳制电位。该刺激程序每15s重复一次,持续记录。化合物的抑制效应通过加药前后的电流变化来进行计算,而IC50数值由Hill方程进行拟合所得。
表1:本发明代表性化合物在两种浓度下对Nav1.7的抑制率
表2 化合物Z-164对其他离子通道的选择性
化合物 | Z-164 | 化合物 | Z-164 |
Nav1.7(IC<sub>50</sub>/nM) | 24.57 | Nav1.8(IC<sub>50</sub>/nM) | 18900 |
Nav1.5(IC<sub>50</sub>/nM) | 6160 | Cav3.2(IC<sub>50</sub>/nM) | >30000 |
从表1可以看出,本发明代表性化合物对Nav1.7具有较高的抑制活性。此外研究发现,相较于对比化合物(如C1-C11),五元(吡咯环)和六元(哌嗪环)含氮杂环上氮原子和苯环或吡啶环上碳原子直接相连时,对Nav1.7的抑制活性有明显的影响,研究表明当氮原子不与苯环或吡啶环直接相连时,即苯环或吡啶环通过亚甲基或羰基等基团与氮原子相连时,对Nav1.7的抑制活性有明显的降低(如C1与Z-197,C4与Z-164)。
此外,若将苯环或吡啶环通过亚甲基或羰基等基团与氮原子相连,并且R6为甲基时,对Nav1.7的抑制活性有明显的降低(如C2与Z-196,C11与Z-197)。
从表2可以看出,化合物Z-164还显示了对其他离子通道,特别是Nav1.5、Nav1.8钠离子通道和钙离子通道的选择抑制活性。
测试例2:对hERG钾离子通道的作用
2.1 细胞培养
2.1.1 本试验所用的细胞为转染有hERG cDNA与稳定表达hERG通道的CHO细胞系(由丹麦Sophion Bioscience公司提供),细胞代数为P15。细胞培养在含有下列成分的培养基中(皆来源于Invitrogen):Ham’s F12培养基,10%(v/v)灭活的胎牛血清,100μl/ml潮霉素B,100μl/ml Geneticin。
2.1.2 CHO hERG细胞生长于含上述培养液的培养皿中,并在37℃、含5%CO2的培养箱中进行培养。电生理实验之前24到48小时,CHO hERG细胞被转移放置于培养皿中的圆形玻璃片上,并在以上相同的培养液及培养条件下生长。每个圆形玻璃片上CHO hERG细胞的密度需要达到绝大多数细胞是独立、单个的要求。
2.2 实验溶液
如表3所示,下列溶液(由Sophion提供)用于电生理记录。本试验所用试剂由Sigma提供。
表3 细胞内液与外液的组成成分
2.3 电生理记录系统
本实验采用手动膜片钳系统(HEKA EPC-10信号放大及数字转换系统,购自德国HEKA Electronic)作全细胞电流的记录。表面生长有CHO hERG细胞的圆形玻璃片被放置于倒置显微镜下的电生理记录槽中。记录槽内以细胞外液作持续灌流(大约每分钟1毫升)。实验过程采用常规全细胞膜片钳电流记录技术。如无特殊说明,实验都是在常规室温下进行(~25℃)。细胞钳制在-80mV的电压下。细胞钳制电压去极化到+20mV以激活hERG钾通道,5秒后再钳制到-50mV以消除失活并产生尾电流。尾电流峰值用作hERG电流大小的数值。上述步骤记录的hERG钾电流在记录槽内持续的细胞外液灌流下达到稳定后则可以叠加灌流待测试药物,直到药物对hERG电流抑制作用达到稳定状态。一般以最近的连续3个电流记录线重合作为判断是否稳定状态的标准。达到稳定态势以后以细胞外液灌流冲洗直到hERG电流回复到加药物之前的大小。一个细胞上可以测试一个或多个药物,或者同一种药物的多个浓度,但是在不同药物之间需要以细胞外液冲洗。Cisapride(西沙比利,购自Sigma)被用于实验中作为阳性对照以保证所使用的细胞质量正常。
2.4 化合物处理和稀释
化合物先用DMSO溶解成10mM的浓度,然后再直接用细胞外液将化合物1000倍稀释成最终的10μM测试浓度。化合物测试液中DMSO的最终浓度为等于0.1%。阳性对照Cisapride(西沙比利)的测试浓度为0.1μM。所有贮备液和测试溶液都经过常规的5-10分钟的超声和振荡以保证化合物完全溶解。
2.5 数据分析
试验数据由HEKA Patchmaster(V2x73.2),Microsoft Excel以及Graphpad Prism5.0提供的数据分析软件进行分析。实验结果如表4所示。
表4 本发明代表性化合物对hERG钾离子通道的抑制
化合物 | hERG抑制浓度IC50(μM) |
Z-164 | >10μM |
Z-172 | >10μM |
Z-173 | >10μM |
Z-177 | >10μM |
Z-178 | >10μM |
Z-183 | >10μM |
Z-186 | >10μM |
Z-187 | >10μM |
Z-189 | >10μM |
从表4可以看出,本发明代表性化合物对hERG钾离子通道的抑制活性很小,因此对钾离子通道具有选择性抑制。
测试例3:冷刺激痛觉超敏法SNL
实验动物为雄性Sprague-Dawley大鼠,实验开始时体重140-150g。实验用动物均采购于斯莱克公司,购买后采用自由采食的方式进行食物和水供应,分笼饲养,4只/笼,采用动物尾部标记法进行动物标记。
检测化合物及分组:
溶剂组(Vehicle):5%二甲基乙酰胺(国药科技),5%solutol(Sigma)和90%生理盐水
阳性对照物:普瑞巴林;
待测药物:化合物Z-164;
阳性对照物和待测药物的溶剂成分为5%二甲基乙酰胺,5%solutol和90%生理盐水。
阳性对照物和测试物分别以剂量30mg/kg口服2小时后抑制大鼠脊神经结扎造成的冷痛觉超敏,如表5所示
表5 化合物在脊神经结扎大鼠中药效测试分组
30mg/kg化合物Z-164:称取148.11mg Z-164,加入1.23mL二甲基乙酰胺,待完全溶解后加入1.23mL solutol,震荡混匀后加入90%生理盐水定容至21.44mL,充分混匀后口服给药。
30mg/kg普瑞巴林:称取129.48mg普瑞巴林,加入1.08mL二甲基乙酰胺,待完全溶解后加入1.08mL solutol,震荡混匀后加入90%生理盐水定容至21.58mL,充分混匀后口服给药
实验方法:
1.1.脊神经结扎模型
·手术过程执行无菌操作。
·手术器械(剪刀,镊子,手术刀,手术棉,缝合线,撑开器)在手术前已消毒。
·使用戊巴比妥那(50mg/kg,腹腔注射)麻醉动物。挤压动物脚趾以确认动物手术前已经完全麻醉。在动物眼部涂抹眼用软膏以防止动物角膜干燥。
·剃去动物下半身手术区域毛发,使用碘伏和70%乙醇对手术区域皮肤消毒三遍。待皮肤干燥后开始手术。
·使用手术刀在动物腰部荐骨后部开一纵向切口,暴露左侧椎旁肌,使用撑开器分离肌肉组织以暴露脊椎骨。
·分离左侧脊神经L5和L6,使用6-0丝线结扎。
·缝合伤口。
·清洁手术器械,使用热珠灭菌器灭菌。
·手术后将动物放置在电热毯上,皮下注射5mL生理盐水以防止脱水。等动物完全苏醒后(可自由活动)将动物放回笼中。
1.2.冷痛觉超敏基线测试和分组
给药前两天,对大鼠进行冷痛觉超敏基线测试,使用移液器将100μl丙酮涂在动物术侧后足部皮肤。记录动物在一分钟内拍打,缩脚,抬脚,舔舐术侧足部的时间。丙酮测试共进行两次,两次间隔10分钟。两次时间之和记录为大鼠冷痛觉超敏反应时间。根据给药前一天的冷痛觉超敏反应测试结果将动物随机分组。
1.3.冷痛觉超敏测试
给药两小时后,使用移液器将100μl丙酮涂在动物术侧后脚趾部皮肤。记录动物在一分钟内拍打,缩脚,抬脚,舔舐受影响的脚部的时间。丙酮测试共进行两次,两次间隔10分钟。两次时间之和记录为大鼠冷痛觉超敏反应时间。
1.4.给药
冷刺激痛觉测试2小时前口服给药。
1.5.数据收集和分析
使用Excel软件收集数据。使用Prism软件分析数据。
结论:
表6 大鼠冷痛觉超敏测试结果(化合物Z-164)
实验结果如图1和图2所示,结果表明,口服2小时后,本发明化合物Z-164在脊神经结扎大鼠模型中具有抑制大鼠脊神经结扎诱导的冷痛觉超敏效果,在大鼠体内神经痛模型中是有统计学意义的抑制效果。
图2中,化合物Z-164在脊神经结扎大鼠中的药效,**p<0.01,***p<0.001与溶剂组比较,使用单因素方差分析附加Dunnett多重比较检验。口服化合物Z-164和阳性对照物30mg/kg两小时后分别抑制大鼠脊神经结扎诱导的冷痛觉超敏。
测试例4:代谢稳定性测试
1.缓冲液的配制
缓冲液A:配制1L含有1mM EDTA(Sigma,V900157-100G),100mM的磷酸二氢钾溶液。
缓冲液B:配制1L含有1mM EDTA,100mM的磷酸氢二钾溶液。
缓冲液C:取700mL缓冲液B,用缓冲液A滴定,调至PH为7.4即可。
2.待测化合物和阳性对照药(酮色林(Sigma S006-10MG))的配制
2.1取10mM待测化合物和10mM酮色林各10uL,再各加190uL的纯乙腈,分别配成500uM待测化合物和酮色林溶液。
2.2取20uL(20mg/mL)人肝微粒体(Corning Lot.NO.4133007)储存液加入到513.4uL的缓冲液C,在湿冰上操作。配制得到0.75mg/mL肝微粒体溶液。
2.3各取1.5uL上述待测化合物和酮色林溶液,分别加入到498.5uL(0.75mg/mL)的肝微粒体溶液中,在湿冰上操作。配制得到1.5uM待测化合物混合液和酮色林混合液。
2.4按照时间点0、5、15、30、45、60min,每孔30uL,分别将待测化合物混合液和酮色林混合液分装到反应板上,在湿冰上操作。
2.5称取5mg还原型辅酶II(Roche,10621706001),溶于1mL缓冲液C中。配制成6mM还原型辅酶II溶液。将还原型辅酶II溶液分装到反应板中。
2.6将丙米嗪溶成10mM的溶液,取100mL空白乙腈,加入10uL丙米嗪溶液。配成内标。
2.7在0min,每孔加入135uL含有内标的冰乙腈(Merck(Lot.1778229518)),再加入15uL缓冲液C。
2.8将反应板放入37度水浴恒温箱内预热5min。在反应板中,每孔加15uL还原型辅酶II溶液开始反应并计时。在5、15、30、45、60min时间点,每孔加入135uL含有内标的冰乙腈终止反应。
2.9将反应板用铝膜封好,放在震荡混合器上,500rpm,5min。再将反应板放在离心机中离心,15min,3750rpm。
2.10取样品和纯水按照1∶1比例稀释,LC/MS检测。将得到的数值按照以下公式计算得到如表7所示的半衰期和清除率。
半衰期:0.693/K(孵化时间与浓度对数值作图出来的斜率)
清除率:(0.693/半衰期)*(1/蛋白质浓度(0.5mg\mL))*(比例因子)
其中K值和比例因子为本领域技术人员根据现有方法以及肝微粒体产品说明书记载的方法计算得到的。
表7 人肝微粒体代谢稳定性实验结果
从表7可以看出,本发明化合物具有很好的代谢稳定性,研究发现取代基R6的变化对代谢稳定性有明显的影响,尤其地,当由环丙基变为甲基时,代谢稳定性明显降低(如C12与Z-173,C13与Z-164)。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (12)
2.如权利要求1所述的化合物、或其药学上可接受的盐,其特征在于,R1、R3各自独立地为氟、氯、甲基、乙基、正丙基、异丙基或环丙基。
3.如权利要求1所述的化合物、或其药学上可接受的盐,其特征在于,R2和R4为氢,且R1、R3各自独立地为氟、氯、乙基或环丙基。
4.如权利要求1所述的化合物、或其药学上可接受的盐,其特征在于,A为苯基;所述的苯基为取代的或未取代的;且所述的取代是指基团中的1-5个氢被选自下组的取代基所取代:卤素、C1-3烷基、卤代C1-3烷基、C1-3烷氧基、卤代C1-3烷氧基和C3-6环烷基。
6.如权利要求5所述的化合物、或其药学上可接受的盐,其特征在于,R1’、R2’、R3’、R4’、R5’各自独立地为氢、氟、氯、甲基、乙基、三氟甲基、三氟甲氧基、甲氧基或环丙基。
7.如权利要求5所述的化合物、或其药学上可接受的盐,其特征在于,R21、R31、R41、R51各自独立地为氢、氟、氯、甲基、乙基、三氟甲基、三氟甲氧基、甲氧基或环丙基。
8.如权利要求1所述的化合物、或其药学上可接受的盐,其特征在于,R0为氢。
11.一种药物组合物,所述组合物包括权利要求1至10中任一项所述的化合物、或其药学上可接受的盐;以及药学可接受的载体。
12.如权利要求1至10中任一项所述的化合物、或其药学上可接受的盐,或如权利要求11所述药物组合物在制备治疗疾病或病症的药物中的应用,所述疾病或病症选自疼痛、抑郁症、心血管疾病、呼吸系统疾病、精神疾病或其组合。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610079358 | 2016-02-03 | ||
CN2016100793587 | 2016-02-03 | ||
PCT/CN2017/072470 WO2017133591A1 (zh) | 2016-02-03 | 2017-01-24 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108430969A CN108430969A (zh) | 2018-08-21 |
CN108430969B true CN108430969B (zh) | 2020-06-02 |
Family
ID=59499426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780005514.8A Active CN108430969B (zh) | 2016-02-03 | 2017-01-24 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10815197B2 (zh) |
EP (1) | EP3412653A1 (zh) |
JP (1) | JP2019505508A (zh) |
KR (1) | KR20180086259A (zh) |
CN (1) | CN108430969B (zh) |
AU (1) | AU2017215697A1 (zh) |
CA (1) | CA3011169A1 (zh) |
WO (1) | WO2017133591A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110300745A (zh) * | 2017-07-24 | 2019-10-01 | 上海海雁医药科技有限公司 | 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016124141A1 (zh) * | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
AU2017215697A1 (en) * | 2016-02-03 | 2018-07-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | N-sulfonyl benzamide derivative with heterocyclic substituent, preparation method therefor and pharmaceutical application thereof |
WO2020199683A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海海雁医药科技有限公司 | 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
CN115057768A (zh) * | 2022-08-19 | 2022-09-16 | 济南国鼎医药科技有限公司 | 一种3,5-二氯-4-甲氧基苯甲酸的合成方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012007869A2 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2015051043A1 (en) * | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
WO2015078374A1 (en) * | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
CN104718188A (zh) * | 2012-05-22 | 2015-06-17 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
WO2016124139A1 (zh) * | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008540665A (ja) * | 2005-05-19 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なビアリール |
TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
EP2870138B1 (en) | 2012-07-06 | 2018-08-22 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
CA2887845C (en) * | 2012-10-15 | 2020-12-15 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
AU2017215697A1 (en) * | 2016-02-03 | 2018-07-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | N-sulfonyl benzamide derivative with heterocyclic substituent, preparation method therefor and pharmaceutical application thereof |
-
2017
- 2017-01-24 AU AU2017215697A patent/AU2017215697A1/en not_active Abandoned
- 2017-01-24 KR KR1020187019155A patent/KR20180086259A/ko not_active Application Discontinuation
- 2017-01-24 JP JP2018534660A patent/JP2019505508A/ja not_active Withdrawn
- 2017-01-24 EP EP17746911.1A patent/EP3412653A1/en not_active Withdrawn
- 2017-01-24 US US16/068,627 patent/US10815197B2/en active Active
- 2017-01-24 CA CA3011169A patent/CA3011169A1/en not_active Abandoned
- 2017-01-24 WO PCT/CN2017/072470 patent/WO2017133591A1/zh active Application Filing
- 2017-01-24 CN CN201780005514.8A patent/CN108430969B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012007869A2 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
CN104718188A (zh) * | 2012-05-22 | 2015-06-17 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
WO2015051043A1 (en) * | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
WO2015078374A1 (en) * | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
WO2016124139A1 (zh) * | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
WO2016124141A1 (zh) * | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110300745A (zh) * | 2017-07-24 | 2019-10-01 | 上海海雁医药科技有限公司 | 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用 |
CN110300745B (zh) * | 2017-07-24 | 2023-03-31 | 上海海雁医药科技有限公司 | 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108430969A (zh) | 2018-08-21 |
US10815197B2 (en) | 2020-10-27 |
JP2019505508A (ja) | 2019-02-28 |
US20190023654A1 (en) | 2019-01-24 |
CA3011169A1 (en) | 2017-08-10 |
EP3412653A1 (en) | 2018-12-12 |
WO2017133591A1 (zh) | 2017-08-10 |
KR20180086259A (ko) | 2018-07-30 |
AU2017215697A1 (en) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108430969B (zh) | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 | |
CN106795149B (zh) | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 | |
JP7097358B2 (ja) | アルファvインテグリン阻害剤としての3-置換プロピオン酸 | |
CN101511796B (zh) | 咪唑衍生物 | |
US10336697B2 (en) | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | |
TWI434842B (zh) | Azole compounds | |
CN107406380B (zh) | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 | |
MX2007012449A (es) | Compuestos y composiciones que contienen diaril-amina, y su uso como moduladores de los receptores nucleares de hormonas esteroideas. | |
WO2008104524A1 (en) | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase | |
BR112013023048B1 (pt) | Compostos de guanidina ou um sal dos mesmos, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para tratar nefropatia diabética ou edema macular diabético | |
EP2833879A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
CN114008028B (zh) | 抑制癌细胞生长的嘧啶衍生物及其医药用途 | |
IL184268A (en) | N-(heteroaryl)-1h -indole-2-carboxamide compounds, process for preparing said compounds, medicament, pharmaceutical composition and use thereof | |
WO2021032209A1 (zh) | 抗流感病毒化合物及其制备方法和用途 | |
KR20220141331A (ko) | P2x3 조정제 | |
CN116675684B (zh) | 含炔基稠环类衍生物拮抗剂、其制备方法和应用 | |
US11999720B2 (en) | Pyrazolylacylpyrazoline compounds and method for treating pain | |
CN111094300B (zh) | 苯并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
WO2024002379A1 (zh) | 一种用作wdr5抑制剂的化合物或其可药用盐及其应用 | |
WO2020147848A1 (zh) | 三环取代的氧杂螺环衍生物、其制法与医药上的用途 | |
WO2023025277A1 (zh) | 含芳环类生物拮抗剂、其制备方法和应用 | |
WO2020199683A1 (zh) | 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途 | |
KR20200125967A (ko) | 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |